Deliver logo
Speaker Bio
Bruce Levine
Barbara and Edward Netter Professor in Cancer Gene Therapy
Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania
Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. He received a B.A. (Biology) from Penn and a Ph.D. in Immunology and Infectious Diseases from Johns Hopkins. First-in-human adoptive immunotherapy trials include the first use of a lentiviral vector, the first infusions of gene edited cells, and the first use of lentivirally-modified cells to treat cancer. Dr. Levine has overseen the production, testing and release of 3,000 cellular products administered to >1,300 patients in clinical trials since 1996. He is co-inventor of the first FDA approved gene therapy (Kymriah), chimeric antigen receptor T cells for leukemia and lymphoma, licensed to Novartis. Dr. Levine is co-inventor on 28 issued US patents and co-author of >180 manuscripts and book chapters with a Google Scholar citation h-index of 89. He is a Co-Founder of Tmunity Therapeutics, a spinout of the University of Pennsylvania. Dr. Levine is a recipient of the William Osler Patient Oriented Research Award, the Wallace H. Coulter Award for Healthcare Innovation, the National Marrow Donor Program/Be The Match ONE Forum 2020 Dennis Confer Innovate Award, serves as President of the International Society for Cell and Gene Therapy, and serves on the Board of Directors of the Alliance for Regenerative Medicine. He has written for Scientific American and Wired and has been interviewed by the NY Times, Wall Street Journal, Washington Post, NPR, Time Magazine, National Geographic, Bloomberg, Forbes, BBC, and other international media outlets.
Yangbing Zhao
President and Chief Scientific Officer
UTC Therapeutics
Dr. Yangbing Zhao is the President and CSO of UTC Therapeutics Inc. He received an MD and PhD in Immunology from the Third Military Medical University in Chongqing. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells for allogeneic bone marrow transplantation. For the next two years he was a research associate at Duke University Medical Center, where he worked on RNA transfected dendritic cell vaccines against cancers. In 2003, he joined Dr. Steven Rosenberg’s group as a senior research fellow at the Surgery Branch of the National Cancer Institute, where his research work directly led to clinical trials of treating cancer patients with T cells against NY-ESO-1, Her2/Neu, CD19 or VEGFR. He joined the faculty of the Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine in 2009 as an Adjunct Associate Professor and the Director of T Cell Engineering Lab. The research work at the University of Pennsylvania let to multiple clinical trials using CART or TCR T to treat cancer patients. Dr. Zhao has more than 20 years’ experiences in T cell engineering and his seminal work directly led to multiple clinical trials of treating cancer patients with T cells modified with TCR, CARs and CRISPR genome editing. Dr. Zhao has over 50 TCR-T and CART related publications and filed over 90 patents. Dr. Zhao is co-founder of Tmunity Therapeutics.
Yuling Li
CEO and Co-Founder
Innoforce Pharmaceuticals
 Dr. Yuling Li is a seasoned executive with proven experience in biopharmaceutical development from clinical to commercialization. She was a R&D Director and Fellow at MedImmune/AstraZeneca and Senior Director of Purification Sciences at HGS (now GSK). She played key roles in the development of 3 approved products and contributed to over 30 clinical development programs.
In 2014, she received the Rising Star Award from the Healthcare Businesswomen’s Association. She served as the President of the Chinese Biopharmaceutical Association and co-founded the Alliance of ALL-CABPA in 2008.
Dr. Li has authored over 40 publications and is the primary inventor for seven issued patents. She received her Ph.D. from Robert Wood Johnson Medical School at Rutgers University.
玉玲博士是一位有着丰富经验的企业管理者,在生物制药工艺开发及生产领域有着资深的实战经验。李博士曾任AstraZeneca(阿斯利康)旗下美国生物制药公司MedImmune的科技和工艺研发主任,以及美国人类基因科学公司(现为葛兰素药业)的资深主任。李博士参与了30多个药品的注册申请,并且成功主持报批了其中三个产品。
2014年,李博士获得了医疗行业女企业家协会新星奖,曾担任美国华人生物医药科技协会(CBA)2007‐2008的会长,CBA董事会和顾问董事会的成员,也是美华生物医药联盟(All‐CABPA) 的发起人和创任会长之一(该联盟于 2008 年 5 月成立)。
李博士发表了40多篇科学论文,有5项批准专利。李博士在罗格斯大学RWJ医学院获得博士学位。
Licheng Ding
Senior Reviewer
Shanghai Centre for Drug Evaluation and Inspection
丁力承,现上海药品审评核查中心药品检查员,主要从事生物制品生产检查,包括药品生产许可检查、药品注册生产现场检查、药品GMP。曾在生物制品生产企业从事质量管理、验证及工程工艺设计等工作。
Xiaodong Song
Chief Executive Officer
UTC Therapeutics
宋晓东博士现任优替济生生物医药有限公司首席执行官,专注开发肿瘤免疫治疗细胞药物。在强生公司任职期间,宋博士代表强生深度参与了南京传奇BCMA CART的合作项目,成功获得了全国第一个CART注册临床批件和国内CART药物在美国的第一个注册临床批件。在上海恒润达生生物科技有限公司任副总经理期间,宋博士带领团队在1998获得了全国仅有的7个CAR-T注册临床批件中的3个,并在上海中山医院率先启动了全国第一个CART注册临床试验。宋博士还利用特殊审评通道,成功获得了国内CART药物在以色列的第一个临床批件。
宋博士曾任美国强生公司全球法规注册事务部总监并在强生工作6年。他是强生亚太地区药品生产领导团队的成员之一。宋博士负责监督和支持强生公司在中国以及亚太地区有关药物研发,药品生产和注册申报中的法规事务。宋博士也曾担任过RDPAC药学理事会主席。他一直积极参加与中国药品监管和法规注册相关的活动,并与国家药品监督管理局以及各行业协会合作共同促进中国医药行业法规的健全和发展。应国家药监局的邀请,宋博士起草了第一稿细胞治疗产品的GMP附录。
在加入强生公司之前,宋博士曾在美国辉瑞公司工作16年。他曾在辉瑞公司全球药物研发中心,全球药品生产总部和全球仿制药专利侵权调查部门任职。宋博士曾担任辉瑞全球仿制药专利侵权调查部门的负责人。他还创立了辉瑞制药公司辅料化学协会并担任首届主席,领导开展与辅料相关的技术研究和制剂开发。宋博士也曾是辉瑞全球药物研发中心新药剂型研发团队的主要成员。
在加入辉瑞公司之前,宋博士在美国康涅狄格州的奥林公司接受生物化学博士后训练。他于1995年在美国路易斯安娜大学获得药物化学博士学位,于1990年在中国科学技术大学获得分析化学硕士学位,于1987年在浙江工业大学获得分析化学学士学位。
Stephan Grupp
Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, Medical Director of The Cell and Gene Therapy Lab
Children’s Hospital of Philadelphia (CHOP)
Stephan Grupp, MD PhD, is the Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, and Medical Director of The Cell and Gene Therapy Lab at the Children’s Hospital of Philadelphia (CHOP), as well as the Yetta Dietch Novotny Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine.
Dr. Grupp graduated from the University of Cincinnati after completing the MD/PhD program with a PhD in Immunology.
He completed pediatric residency at the Boston Children’s Hospital, followed by a fellowship in Pediatric Hematology/Oncology at the Dana Farber Cancer Institute and postdoctoral work in Immunology at Harvard University. He then joined the faculty at Harvard University until 1996, when he came to CHOP. His primary area of clinical research is the use of CAR T and other engineered cell therapies in relapsed pediatric cancers. He led all of the pediatric ALL trials of CTL019 (now approved as Kymriah), including the largest and most successful engineered T cell therapy clinical trial conducted to date (1, 2), as well as the global registration trial for CTL019 (3). As a result of this work, he presented the Clinical Perspective at the July 2018 FDA ODAC meeting, at which reviewers voted 10-0 for recommendation of approval for Kymriah in pediatric ALL. His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers. Dr. Grupp is a reviewer for several journals and the author of over 200 peer-reviewed journal articles, as well as numerous abstracts and book chapters.
Hartmut Tintrup
Global Head of Business Development & Partnering, Cell & Gene Technologies Business Unit
Lonza
Dr. Hartmut Tintrup is the Global Head of Business Development & Partnering activities for Lonza’s Cell & Gene Technologies Business Unit. He started at Lonza in 2017 with the responsibility of Business Development & Partnering Activities for the EMEA region. Dr. Tintrup has more than 15 years of experience in the biotech industry spanning leading positions in R&D, industrial sales as well as partnering activities including licensing. He holds a PhD in Biochemistry received at the Max-Planck-Institute for Brain Research in Frankfurt/Germany.
Mickey Koh
Director-Stem Cell Transplantation
St George’s Hospital and Medical School
Medical Director
Cell Therapy Programme
Health Sciences Authority, Singapore
Dr Mickey Koh received his medical degree in Singapore and all his subsequent specialist Haematology training including his FRCPath, MRCP and PhD in London.
He holds several joint positions. Dr Koh is a Consultant Haematologist and Senior Lecturer at St George’s Hospital and Medical School, London, UK. He is also the Programme Director of the Stem Cell Transplant Programme as well as being the Clinical Lead for Bone Marrow Failures and Rare Haematological Diseases at St George’s Hospital.
At the same time, he is also the Programme Director of the Cell Therapy Facility in Singapore involved in cell therapy trials cross haemato-oncology and regenerative medicine. He was also previously the Deputy Director of the National Blood Service in Singapore
Dr Koh sits on the board of various transplant and cell therapy organizations including being the Chairperson of the Cell Therapy Working Party at International Society Blood Transfusion and Chairperson of the Graft Processing/Cellular Therapies subcommittee of Worldwide Network for Blood and Marrow Transplantation. He is a past Board member of the International Society of Cellular Therapy Therapy and is Vice _president of the ISCT presidential Task force on Unproven therapies. Dr Koh has also been an advisor to the World Health Organisation on matters of transfusion and cellular therapies. He is widely published and is also on the editorial board of various peer reveiwed journals
Steve Oh
Institute Professor and Director, Stem Cell Group
Bioprocessing Technology Institute, A*STAR
Dr. Steve Oh obtained his PhD from Birmingham University, UK (1990) and is the Director of Stem Cell Bioprocessing and Institute Scientist, Stem Cell Group. He holds several industry leadership roles e.g. Past Vice President of International Society of Cell and Gene Therapy (ISCT); Member of International Society of Stem Cell Research (ISSCR); Member of International Stem Cell Banking Initiative (ISCBI); Vice President of Stem Cell Society Singapore (SCSS). He is also an Adjunct Associate Professor at NTU, PhD Supervisor at A*STAR Graduate Academy and has received research funding grants ranging from SGD 10 to 25 million. He has 42 Patents, granted and pending, 107 scientific publications, written the book “Sensational Stem Cell: How to cure medical complications.” and created 2 companies: Veristem and Zenzic Labs.
Our research is focused on human adult and pluripotent stem cell bioprocessing. Our team has developed a range of patent families for the manufacture of mesenchymal stem cells, reprogrammed human induced pluripotent stem cells and created neural cells, cardiomyocytes, blood cells, cartilage, bone and retinal pigment epithelial cells at bioreactor scale using a range of microcarrier technologies including biodegradable ones. Most recently, we have achieved a novel method of directed differentiation using CRISPR technology that will accelerate therapeutic applications of stem cells. A complimentary technology that has been developed is the use of microfluidics for separations of cell and particulates.
Richard Wang
Founder & CEO
Neukio Biotherapeutics
Richard received degrees of B.S of Cell Biology from the University of Science & Technology of China, Ph.D of Molecular Biology from the University of Maryland, Baltimore, and MBA from Xavier University, Cincinnati in the US. He obtained his post-doctoral training at the National Institutes of Health, Baltimore, USA. Richard now is the CEO of Fosun Kite Biotechnology. Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients. Richard is very experienced in biopharmaceutical industry. Having spent close to 20 years in R&D and management positions in both the US and China, he has taken senior roles and increasing leadership responsibilities in Procter & Gamble Pharmaceutical, Bristol-Myers Squibb in the US, AstraZeneca Innovation Center and GSK R&D Center in China. Prior to Fosun Kite, Richard was the Chief Operation Officer of Cellular Biomedicine Group (NASDAQ: CBMG), where he was in charge of the company’s immunotherapy pipeline including manufacturing, clinical development and registration, and the stem cell business unit.
Biliang Hu
CEO
Hunan Siweikang Therapeutic
Biliang Hu obatined PhD degree in University of Southern California. Then he continued Postdoc training of CART cell immunotherapy under Dr. Carl June’s mentoring in University of Pennsylvania, and has developed the fourth generation of CART secreting IL-18. After postdoc training, he founded celledit in US and Siweikang Therapeutics in China to develop the SAFET platform to resolve CRS during CART therapy.
Yangbing Zhao
President and Chief Scientific Officer
UTC Therapeutics
Dr. Yangbing Zhao is the President and CSO of UTC Therapeutics Inc. He received an MD and PhD in Immunology from the Third Military Medical University in Chongqing. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells for allogeneic bone marrow transplantation. For the next two years he was a research associate at Duke University Medical Center, where he worked on RNA transfected dendritic cell vaccines against cancers. In 2003, he joined Dr. Steven Rosenberg’s group as a senior research fellow at the Surgery Branch of the National Cancer Institute, where his research work directly led to clinical trials of treating cancer patients with T cells against NY-ESO-1, Her2/Neu, CD19 or VEGFR. He joined the faculty of the Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine in 2009 as an Adjunct Associate Professor and the Director of T Cell Engineering Lab. The research work at the University of Pennsylvania let to multiple clinical trials using CART or TCR T to treat cancer patients. Dr. Zhao has more than 20 years’ experiences in T cell engineering and his seminal work directly led to multiple clinical trials of treating cancer patients with T cells modified with TCR, CARs and CRISPR genome editing. Dr. Zhao has over 50 TCR-T and CART related publications and filed over 90 patents. Dr. Zhao is co-founder of Tmunity Therapeutics.
Peihua ( Peggy ) Lu
Medical Executive President
Lu Daopei Hosptial and Lu Daopei Institute of Hematology
 Dr. Lu graduated from Peking University  Medical School, and had her residency training at the University of Nebraska Medical Center in USA. 
She completed her hematology and  oncology fellowship at Stanford University  Medical Center. 
• American Board Certified Hematologist & Oncologist, with American and Chinese Medical License.
• Member of ASH,ASCO & CAHON
• Chairman of Hematology Specialty Committee of  Chinese Non-government Medical Institutions Association (CNMIA)
• Member of Chinese Marrow Donor Program(CMDP) Expert Committee
• Member of Chinese Society of Clinical Oncology (CSCO) Anti-Leukemia Alliance Expert Committee
• Member of the Hematology Translational Medicine Committee of China Anti-Cancer Association(CACA)
• Vice Chairman of Sanhe Private Hospital Industry Association
• She has had many awards which including National Cancer Institute individual fellowship award, physician scientist award  (K011)
Grace Zhou
Chief Executive Officer
ImmVira Group Company
Grace Zhou, professor, doctoral supervisor, national high-level distinguished expert, the only winner of the 2019 International "Anti-Virus Female Scientist Award". Co-founder, CEO and Chairman of ImmVira Group.
Grace Zhou is a Ph.D. from the Shanghai Institute of Biochemistry, Chinese Academy of Sciences, and a former associate professor of the Department of Microbiology at the University of Chicago. She has devoted more than 20 years of research in the field of antiviral infection and herpes oncolytic virus tumor immunotherapy. With scientific research projects at all levels and provinces and cities, nearly 50 SCI papers have been published as the first author or corresponding author, with a citation index of 1055; more than 10 international invention patents in the United States, Europe, and Asia have been obtained, and nearly 20 international patents have been applied for. Served as an editorial board member of the international journal Frontiers Virology, and reviewed manuscripts for Proc Natl AcadSci US A, Mbio and Journal of Virology. Dr. Zhou is the international inventor of herpes-targeted oncolytic viruses. She has changed the way herpes viruses enter host cells for the first time. This research is called the cornerstone of herpes-targeted tumors by international colleagues.
ImmVira was founded by Grace Zhou and other 5 co-founders on May 18, 2015 as a biotechnology company focused on genetically modified oncolytic viruses as potential cancer therapeutics. The company has developed science, technology and know-how to support ongoing research, development and commercialization of best in class oncolytic viruses on the OvPENS (OV+ Patent, Enabling, Novel & Safe) platform.
Lijun Wang
Co-Founder and Chief Technology Officer
Exegenesis Bio
Lijun Wang is a co-founder and CTO of Exegenesis Bio. She has over 20 years biotech industry experience and the most recent 15 years were focused gene therapy viral vector CMC, including process development, process engineering and cGMP manufacturing of viral vectors (AAV, LV, Ad and oHSV). Prior to her venture, working for a well-known CDMO in the field, Brammer Bio (formerly Florida Biologix), she has led a number of viral vectors projects from early process development to cGMP CTM batches using multiple production platforms from early to late phase clinical applications. She is a successful leader dedicated to bring bench scale processes to clinical stage ready and future commercial-viable.
Min Wang
Chief Technology Officer
PersonGen BioTherapeutics
汪敏博士毕业于中国科学技术大学,获得细胞生物学专业博士学位,现任博生吉医药科技(苏州)有限公司技术总监。
汪敏博士致力于CART细胞药物的开发与产业化事业。她赴德国接受美天旎全自动CART工艺培训期间,以其专研、严谨的工作态度,获得了合作方的好评。汪敏博士带领博生吉的CART细胞部门,不仅建立了全自动CART细胞制备工艺平台,而且进行了大量的优化和改进工作,为打造适合中国国情的CART细胞全自动生产线作出了突出的贡献。在汪敏博士的具体领导下,博生吉获得了“靶向CD19嵌合抗原受体T细胞输注剂”的新药临床试验批件,这也是中国首个以全自动工艺获得临床批件的CART项目,为博生吉未来的产业化发展奠定了坚实的基础。
汪敏博士代表公司参加”创响中国“安徽省创新创业大赛决赛,荣获生物医药组第一名。此外,汪敏博士还带领公司技术部门,对多个First-in-class CART新药进行了大量的工艺开发和优化,为博生吉新一代CART细胞药物的IND申报创造了条件。
Dr. Wang received her Phd of Cell Biology from University of Science and Technology of China(USTC), and is currently the Technical Director of PersonGen BioTherapeutics(Suzhou) Co., Ltd.
Dr. Wang is committed to the development and industrialization of CART cell drugs. She led the CART cell department of PersonGen and has not only established the automatic CART cell manufacture platform, but also carried out a lot of optimization and improvement work.Under the leadership of Dr. Wang, PersonGen has obtained the clinical trial approval for "CD19 chimeric antigen receptor T cell infusion agent", which is also the first CART project in China to obtain clinical approval by the whole-automatic process, laying a solid foundation for PersonGen's future industrial development.
On behalf of the company, Dr. Wang participated in the final of the "Innovation and Entrepreneurship Competition of Anhui Province" and won the first place in the biomedical group.In addition, Dr. Wang led the technology department of the company to develop and optimize a number of first-in-class CART new drugs, creating the conditions for PersonGen to apply IND for a new generation of CART cell drugs.
Guo-An Wang
Executive Director of Plasmid & Gene Therapy Development & Manufacturing
Innoforce Pharmaceuticals
Dr. Wang has more than twenty years of experiences in Biochemistry and Molecular Biology and in the development of biologic products. Currently is Executive Director of Plasmid and Gene Therapy Process Development and manufacture at Innoforce Pharmaceuticals in Hangzhou. Prior to joining Innoforce, he is Director of Plasmid Production at Vigene Biosciences in Maryland USA. He obtained his Ph.D in Biochemistry from Shanghai Institute of Organic Chemistry, Chinese Academia of Sciences.
Frank Fan
Chief Scientific Officer
Legend Biotech
Dr. Frank Fan, Chief Scientific Officer of Legend Biotech Co., is the co-founder of the company. Frank received his medical degree at Xi’an Jiaotong University in 1993 and worked as surgical resident in kidney Transplantation Centre of the university before he pursued and obtained his Ph.D. in applied immunology at Hiroshima University. He completed his postdoctoral training at the Hospital for Sick Children, University of Toronto, Canada where he became recognized as an expert in the field of the mechanism of human B cell tolerance. A breakthrough he made in the area was published in Nature Medicine and the knowledge led to a major revision in the clinical guideline of pediatric organ transplantation. He was awarded a “New Key opinion leader” by The International Society of Transplantation in 2006. He published more than 40 peer-reviewed scientific reports in human B cell biology, transplant immunology, and gene therapy. Funded by GenScript, Dr. Fan founded Legend Biotech in 2014 and built an elite R&D team exploring innovative precision cell therapy. In just 3 years, the company grew from a fresh start to a global leader in cell therapy of multiple myeloma. The LCAR-B38M product Dr. Fan invented is the first cell therapy product obtained IND approval from both the CFDA and the FDA.
Bo Li
Chief Executive Officer
GenoImmune Therapeutics
武汉华大吉诺因生物科技有限公司,总经理
广东省精准医学应用学会免疫治疗分会,副主任委员;
深圳市医学学会第一届肿瘤免疫治疗专业委员会,常务委员;
中国医药生物技术协会基因检测技术分会第一届委员会,委员。
研究员,从事基因组学、肿瘤免疫治疗研究;发表包括《Nature》、《CELL》在内的SCI文章28篇,文章累计引用次数超过2300次。主持开发了靶向肿瘤新抗原T细胞药物,获得国内首个肿瘤新抗原药物的临床试验批件。
Xiaoyun Shang
Chief Executive Officer
Suzhou T-Maximum Bio-tech
Life member of Chinese Society of Immunology, director of Immunology Committee of Hubei Cancer Society. Engaged in tumor immunotherapy research for nearly 20 years, involving preclinical and clinical studies of multiple Class I new drug projects. Presided over a number of major national science and technology projects such as "Major New Drug Development". He has applied for or obtained more than 20 national invention patents, obtained eight software copyrights, and published a monograph. Selected as the 2019 Leading Entrepreneur Talent Project in Suzhou Industrial Park. Entrepreneurship projects have won awards in multiple entrepreneurial competitions.
Guanghua Liu
R&D Director
ImmunoChina Pharmaceuticals
刘光华 于清华大学获得博士学位,目前担任北京艺妙神州医药科技有限公司开发总监一职,参与负责了IM19 CAR-T细胞药物的细胞工艺及非临床药理药效毒理研究,完成IM19 IND申报所需非临床研究资料。成功支持IM19 CAR-T细胞注射液获得临床试验批件。
Pengfei Yuan
Chief Technology Officer
EdiGene
Dr. Pengfei Yuan has more than ten years of experience in gene editing technology development and application transformation. He is currently the Chief Technology Officer at EdiGene.
Dr. Yuan is part of the earliest group of Chinese scholars exposed to genome editing technologies. He has made many valuable contributions to improve and develop genome editing technologies. His research results have been published in Nature, Cell, Nature Biotechnology and other top science publications. Dr. Yuan was also the former executive director of many key projects funded by the National Natural Science Foundation of China. His personal honors include being selected as Beijing Science and Technology New Star, Zhongguancun Young Eagle Talent, and winning the first prize of Beijing Youth Excellent Science and Technology Paper.
Dr. Yuan holds a double bachelor's degree and doctorate degree from Peking University. During his PhD and postdoctoral studies, he studied under Professor Wei Wensheng, a well-known expert in the gene editing field. He also has the title of Associate Researcher in the Beijing Natural Science Research Series.
Mingyao Liu
Chairman
Shanghai Bioray Laboratory
Dr. Mingyao Liu received his PhD degree in the University of Maryland College Park (1992), did his postdoctoral training and fellowship in John Hopkins University School of Medicine and California Institute of Technology (Caltech) (from 1993-1998), respectively. He started his independent lab as an assistant professor in 1999 at the Institute of Biosciences and Technology, Texas A&M University and was promoted to tenured full professor in 2006. He was the Dean of the School of Life Sciences, East China Normal University from 2012-2020. Now he is the nationally-endowed professor and the Director of Institute of Biomedical Sciences and Shanghai Key Laboratory of Regulatory Biology in East China Normal University, Shanghai. He is also the founder and Chairman of Shanghai Bioray Laboratories Inc. and two other biotech companies. Dr. Liu's research interests are focused on developing innovative gene editing strategies in cell and gene therapies for cancer and genetic diseases, as well as GPCR-signaling based drug discovery. He has been the PIs for major national scientific research programs from MOST, national key research projects from NSFC, and national new drug discovery projects. He has published more than 350 peer-reviewed journal articles, including Science, Nature, Nature Medicine, Nature Biotechnology, PNAS etc. He has applied for more than 100 patents and won the first prize of National Science and Technology Progress Award in 2012 and the Shanghai Magnolia Memorial Award in 2014. He is the president of Chinese Society for Cancer Cell Biology since 2017.
Wei (William) Cao
Founder, Chairman and CEO
Gracell Biotechnologies
曹卫博士(Ph.D.,B.M.)于2017年5月创立亘喜生物科技集团(纳斯达克股票代码:GRCL),担任董事长兼首席执行官。曹博士在生物技术研发领域深耕超过30年,包括成功(联合)创立了两家在纳斯达克上市的细胞与基因疗法公司。在创立亘喜生物前,曹博士是前纳斯达克上市公司西比曼生物科技集团(前纳斯达克股票代码:CBMG)的联合创始人。该公司致力于开发用于治疗癌症和退行性疾病的专利细胞疗法。2010年8月至 2016年1月,他曾在西比曼担任多个职位,包括首席运营官、首席执行官和董事等。在此之前,曹博士还曾在Chiron公司(诺华和拜耳)以及全球遗传分析行业领导者Affymetrix(赛默飞世尔)公司先后担任科研领域的高管职位。在学术领域,曹博士同样积累颇丰,他曾在哈佛医学院和斯坦福大学医学中心从事免疫药理学领域相关研究,并持有复旦大学上海医学院医学学士学位和美国弗吉尼亚医学院药理学博士学位。值得一提的是,曹博士同时还是80多个国内外细胞治疗技术专利(申请)的主要发明人。
Dr. William (Wei) Cao, Ph.D. B.M., has been the Founder, Chairman and Chief Executive Office of Gracell Biotechnologies Group (Nasdaq: GRCL) since its foundation of May, 2017. Dr. Cao has over 30 years of research and development experience in the biotechnology industry, including founded and co-founded two Nasdaq-listed companies in the field of cell & gene therapies. Prior to founding Gracell, Dr. Cao co-founded Cellular Biomedicine Group, Inc. (formerly Nasdaq: CBMG), a formerly Nasdaq-listed company engaged in the development of proprietary cell therapies for the treatment of cancer and degenerative diseases, and served as COO, CEO and director from August 2010 to January 2016. Before that, Dr. Cao served at senior scientific management positions at Chiron (Novartis and Bayer) and Affymetrix (ThermoFisher). Dr. Cao has extensive research experience in the immune-pharmacology field at Harvard Medical School and Stanford University Medical Center. Dr. Cao holds a Bachelor’s degree in Medicine from Fudan University Medical College in Shanghai, China and a Ph.D. in Pharmacology from The Medical College of Virginia, U.S. Dr. Cao also has over 80 issued patents and applications for advanced cell therapies.
Tony (Bizuo) Liu
Chief Executive Officer, Chief Financial Officer
Cellular Biomedicine Group
Mr. Liu formerly served as the Corporate Vice President at Alibaba Group responsible for Alibaba’s overseas investments. Since joining Alibaba in 2009, Tony held various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for the B2C global e-commerce platform. He was also Chief Financial Officer for HiChina, a subsidiary of Alibaba, a leading internet infrastructure service provider. Prior to joining Alibaba, Tony spent 19 years at Microsoft Corporation where he served in a variety of finance leadership roles. He was the General Manager of Corporate Strategy looking after Microsoft’s China investment strategy and corporate strategic planning process. Tony was a key leader in the Microsoft corporate finance department during the 1990s as the Corporate Accounting Director. He was well recognized within Microsoft for driving an efficient worldwide finance consolidation, reporting, internal management accounting policy process, and showcased Microsoft’s best practices to many Fortune 500 companies in the U.S. Mr. Liu obtained his Washington State CPA certificate in 1992. He had been serving as an Independent Director and Chairman of the Audit Committee for CBMG since March 2013 and was appointed as Chief Financial Officer in January 2014. He was appointed as Chief Executive Officer of the Company in February 2016.
Jianxun Wang
Co-Founder & Chief Scientist
JUNJO Pharmaceuticals
王建勋教授是广东君厚生物医药有限公司的联合创始人兼首席科学家,加州大学圣迭戈分校博士后,现任北京中医药大学特聘教授,博士生导师,深圳北京中医药大学研究院细胞和基因治疗研究所所长。王建勋博士师从美国科学院院士Michael G. Rosenfeld,Christopher K. Glass,在Nature等世界顶级杂志发表多篇论文,为表观遗传学专家,主要探索利用表观遗传性状改变来增强T细胞识别和杀伤肿瘤的功能,实现CAR-T治疗实体肿瘤的突破。曾是美国Sorrento Therapeutics公司资深科学家,建立了CAR-T cGMP生产体系, 具有丰富的细胞治疗标准工业化生产经验。是构建逆病毒,慢病毒等基因载体的国际顶级专家,具有丰富的病毒载体标准工业化生产经验。
Adam Zhao
Chairman
Anlong Bio
Chunlin Zhao, Ph.D
Founder of AnlongMed and AnlongBio. Dr. Zhao is among the first class graduated from Department of Biological Science and Biotechnology at Tsinghua University in 1990. He received his Ph.D of molecular biology at University of Pittsburgh School of Medicine and MBA from University of Chicago in the United States. Dr. Zhao was a senior manager at Pfizer in US. After returning to China in 2003, he founded LongMed Inc., and became partner of CASH Capital and C-Bridge Capital. Dr. Zhao has over 30 years of industry experience and excellent investment track record, invested in Innovent, BerryGenomics, ASLETIS, GKHT and Inmagine. Dr. Zhao is the founding Chairman of Tsinghua Alumni Association for School of Life Sciences,School of Medicine and School of Pharmaceutical Sciences, a senior member of BayHelix group. AnlongMed is a leading fund in Chinese life sciences and health care, focusing on biotech & pharma, medical devices, life sciences and medical services in China. Dr. Zhao also founded AnlongBio, a leading player in genetic medicine in China, focusing on gene therapy, iRNA, mRNA, and other genetic medicines. Outside of his professional life, Dr. Zhao is a DJ, soccer player, ski lover, and has three lovely daughters.
Jimmy Zhang
Founder, Chairman and CEO
AccuGen Group
Dr. Jimmy Zhang has 20+ years of experience and expertise in both large pharmas and start-up companies, in strategy, management, business development, and operations, as well as in venture investments. Jimmy is founder, chairman and CEO of AccuGen Group, focusing on gene and cell therapy. He was a Venture Partner at Lilly Asia Ventures (LAV), and Vice President of Transactions at Johnson & Johnson, where he led the transactional and partnership management activities and strategy in Asia Pacific region in pharmaceuticals, medical devices & diagnostics and consumer products, as well as fund relationship and partnership. Jimmy was the Managing Director, MSD Early Investments – Greater China at Merck & Co., and a member of Merck Research Lab (China) Senior Leadership Team. He was also a Board Director of BeiGene (Beijing) Co, Ltd. and an Advisor Board member of Cenova Ventures. Jimmy was previously SVP at Synergenics (an accelerator founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry), a consultant at McKinsey & Company, a registered patent agent in the Palo Alto office of Morrison & Foerster, and a project manager at Chiron Corporation (now part of Novartis).
Jimmy was a founding member and former Chairman of BayHelix Group. He is an adjunct professor and master degree mentor at Yeehong Business School at Shenyang Pharmaceutical University. He holds an MBA from MIT Sloan School of Management, where he was elected as the treasurer of MIT Graduate Student Council; a PhD in biomedical sciences from University of Texas Southwestern Medical Center at Dallas, where he worked closely with three Nobel Laureates; and a BS in biochemistry from Nanjing University. Jimmy published in Cell, Nature, Neuron, and JBC, and holds multiple patents.
Alvin Luk
Chief Executive Officer
Neurophth Therapeutics
Dr. Alvin Luk is the CEO at Neurophth Therapeutics, Inc., bringing over 29 years of leadership experience in global drug development, strategic portfolio management and clinical development. Prior to joining Neurophth, he has served as Senior Vice President and Chief Medical Officer at Shanghai Henlius Biotech, Inc., and he has held executive roles at various companies such as Spark Therapeutics, Inc. (acquired by Roche), Biogen-Hemophilia (acquired by Sanofi), Bayer Healthcare, Avigen, Inc. (acquired by Sanofi Genzyme) and Tularik, Inc. (acquired by Amgen) of progressive responsibilities since the late 1990s. Until 2003, his early research was primarily investigating gene regulation and expression with the emphasis on rare diseases, oncological diseases, biologics and regenerative medicines. He also served as a member at the industrial board of the US FDA Rare Disease Clinical Design Committee, focusing on optimizing clinical trial design to shorten drug development timeline between 2006 and 2009. Under his leadership in strategic drug development, he has won regulatory marketing approvals of 18 products in neurology, ophthalmology, gene/cell therapy, hematology and cancer therapy as of today.
Dr. Luk has published more than 85 book chapters, scientific and medical articles in highly regarded peer-reviewed journals, including New England Journal of Medicine, Nature, Cell, and Science, and is an inventor on over 10 patent applications. Dr. Luk holds an MBA from Harvard Business School. He is ACRP-certified in clinical research and also received his PhD in Neuroscience from the University of California San Francisco Medical School.
Bin Xiang
Founder and CEO
CommBio Therapeutics
Dr. Bin Xiang, a biologist by training, has solid research experience in disease biology, intestine biology, genome editing, AAV and bacterial vector gene therapy. Dr. Xiang founded CommBio Therapeutics Co., Ltd. in 2019 and devote to develop novel medicine by focusing on intestine biology and bacterial delivery system. Currently, Dr. Xiang is the CEO of CommBio, and the College Advisor at ShanghaiTech University.
Dr. Xiang obtained Ph.D in neurobiology from Fudan University Shanghai Medical in 2001, followed by postdoctoral training in cancer biology at Cold Spring Harbor Laboratory and cancer translational research at Vanderbilt University Medical Center.
In 2008, Dr. Xiang switched career to drug discovery and joined AstraZeneca Innovation Center China working on oncology translational medicine. In 2011, Dr. Xiang joined China Novartis Institutes for Biomedical Research (CNIBR). At Novartis, Dr. Xiang was the project team leader having directed both small molecular drug and AAV gene therapy in oncology and metabolic disease. In addition, Dr. Xiang led an innovation group exploring novel disease mechanism from intestine biology and developing new class of drug approaches including genome editing and gene therapy.
Sander van Deventer
Chief Scientific Officer
Porton Biologics
阿姆斯特丹大学医学博士,风险投资公司Forbion Capital的合伙人,原UniQure 的联合创始人和首席科学官,莱顿大学的转化胃肠病学教授。 Sander 是一位卓越的科学家,发表了400多篇科学论文,组织过多次大型的国际学术会议,指导了40多名博士研究生。1998年,他与人合作创立了阿姆斯特丹分子治疗中心(AMT,即UniQure的前身),开发基于AAV的基因治疗产品。 Sander曾成功创建多个生物制药公司,在开发世界第一个靶向人TNF人鼠嵌合单克隆抗体药物(Remicade)和推动第一个基因治疗药物(Glybera)获得上市许可发挥了关键的作用,现加入博腾生物,任职CSO。
Ling-Jie Kong
Chief Technology Officer
Porton Biologics
中国科学院遗传学研究所硕士,美国北卡罗来纳州立大学生物化学博士,杜克大学Dr. Joseph Nevins实验室的博士后;美国基因与细胞治疗学会基因编辑委员会理事,拥有16项基因治疗的相关专利。孔令洁博士曾在美国默沙东制药公司和美国应用干细胞公司担任研发副首席科学家/副总监和副总裁等重要领导职位,有超过20年的生物制药、基因治疗和细胞治疗经验;参与了默沙东多个药物的研究开发,其中Januvia ® 年销售额超过60亿美元;领导了多项基因治疗和细胞治疗药物的研发,包括推进两个基因治疗和细胞治疗的项目在美国分别进入临床I期和临床II期阶段。
Dr. Ling-Jie Kong got his BS degree in biology from Shandong University and MS degree from Institute of Genetics, Chinese Academy of Sciences. He got his PhD in Biochemistry from North Carolina State University, and postdoc training at Dr. Joseph Nevins Lab at HHMI, Duke University. Dr. Kong has over 20-year experience in drug discovery in oncology, hematology and metabolic diseases. He served as associate principal scientist at Merck and Vice President at Applied StemCell. Dr. Kong is an expert in gene and cell therapy especially gene editing base gene therapy. He has led numerus drug discovery programs including two IND stage programs in gene and cell therapy, applied 16 patents in gene therapy related areas. Most recently he was elected to the Gene Editing Committee of American Society of Gene and Cell Therapy. Dr. Kong Joined Porton Bio as CTO, taking charge the technology development in gene and cell therapy.
Eddie Sun
Strategy Alliance Manager, GC & JP
Thermo Fisher Scientific
Eddie Sun obtained his Ph.D in Biology from University of Nottingham in UK, and started his career in a cell and gene therapy start-up company in China. Later, Eddie served across MNC as technical support and business development, and now supports cell biology business including cell and gene therapy for Thermo Fisher in regions of Great China and Japan.
Eddie focuses introducing Thermo Fisher innovation to regions and bringing regional needs to Thermo Fisher R&D team.
Yan YU
GTCT Integrated Solution Specialist
Pall (China)
于艳,毕业于华东理工大学,药学硕士,于2017年9月加入颇尔公司,担任整体解决方案专家一职。拥有9年的行业经验,她现在主要负责基因及细胞治疗整体解决方案业务的推广,熟悉单抗和基因及细胞治疗等生物制药领域的工艺流程,致力于为客户提供优质的全流程工艺解决方案。
Yan Yu served as GTCT Integrated Solution Specialist of Pall China Biotech with a master’s degree in pharmacy from East China University of Science and Technology. She joined Pall in 2017, with 9 years biotechnology experience, Yan’s currently responsible for business promotion of Pall’s total solutions. With solid knowledge of mAb and GTCT process, she’s dedicated to serve customers’ needs with Pall’s excellent products and services.
Shenghua Xie
Associate Director of Plasmid & Virus R&D
GenScript ProBio
谢胜华,06年毕业于西安交通大学。拥有十二年的病毒载体生产和研发经验,参与过多个细胞治疗病毒载体的工艺开发项目并顺利完成2个中美项目的注册申报,现就职于金斯瑞蓬勃生物,负责质粒病毒载体工艺开发和商业化生产工作。
Shenghua Xie has nearly 12 years’ experience on viral vectors from lab scale to industrial grade after graduated from Xi’an Jiaotong University in 2006. As a key member, he successfully delivered two CMC projects of Gene and Cell therapy in China (NMPA) and US (FDA). Now, Mr. Xie works as a lead of plasmid and virus process development and manufacturing in GenScript ProBio.
Ma Mo
Chief Executive Officer
Eureka Biotechnology
马墨,深圳市深研生物科技联合创始人,公司专注于细胞与基因治疗中的核心生产工艺以及自动化生产设备的开发。公司提供基于稳定细胞系的慢病毒生产系统,无需质粒瞬时转染,使用无血清悬浮工艺,极大的提升慢病毒的产能及一致性。同时公司也提供基于封闭系统的细胞自动化生产设备,实现细胞制备的封闭化与自动化。
MA MO, co-founder of Eureka Biotechnology. Eurekabio focuses on the development of core production processes and automated production equipment in cell and gene therapy. Eurekabio provides a lentivirus production system based on stable cell lines that does not require transient plasmid transfection and uses a serum-free suspension process, which greatly improves the productivity and consistency of lentivirus. At the same time, Eurekabio also provides automated cell production equipment based on closed systems to achieve the closed and automated cell production.
Lei Yu
Chief Executive Officer
UniCAR-Therapy Bio-Medicine Technology
Yu Lei, M.D. / Ph.D., is currently a “Zijiang” Distinguish Professor, Director of the Institute of the Biomedical Engineering and Technology (iBET), East China Normal University, China. He is also a member of Shanghai Pharmaceutical Committee, and member of China Clinical-Research Society of Cell Therapy Specialized Committee; At same time, Dr. Yu was also appointed an Adjunct Professor, Department of Chemical Pharmaceutical and Pharmaceutical and Department of Biological Engineering, University of Utah, US. Dr. Yu is an interdisciplinary experiences in medicine, clinical practice, basic medical research, translational medicine, pharmaceutical research, as well as a successful entrepreneur.
Yi Li
President and Chief Scientific Officer
Guangdong Xiangxue Life Sciences
李懿,英国莱斯特大学博士,国家特聘专家,广东省领军人才,广东香雪精准医疗技术有限公司总裁兼CSO,中国科学院广州生物医药与健康研究院感染与免疫中心研究员,呼吸病研究国家重点实验室兼职研究员。在英国长期从事抗体和T 细胞受体的药物研发,主要论文发表在Nature Biotechnology, Nature Medicine,JBC, Molecular Cancer Therapy 等,开创性地将噬菌体展示技术应用于T细胞受体的定向进化研究,并开发出了全球第一个人源高亲和可溶性TCR,使TCR识别pHLA的亲和性提高了100万倍以上,这是TCR领域的关键性突破。曾在英国 Immunocore 公司领导团队成功研发出了多个高亲和性TCR,最终用于FDA批准的免疫治疗临床研究产品。2012 年回国主导建立了中国第一个高亲和TCR介导的T细胞治疗平台,带领香雪团队研发的第一款特异性TCR-T产品TAEST16001注射液已获得国家药监局批准的全国第一个TCR-T新药临床试验许可。
Yi Li, Ph.D. University of Leicester, UK, the National Distinguished Expert, Leading Talent of Guangdong Province, President and CSO of Guangdong Xiangxue Life Sciences, LTD, Principal Investigator of Center for Infection & Immunity at Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, PI at the State Key Laboratory of Respiratory Diseases. He has been engaged in the development of antibody and T cell receptor drugs in the UK for a long time. Representative papers have been published in Nature Biotechnology, Nature Medicine, JBC, Molecular Cancer Therapy, etc. He pioneered the application of phage display technology to the directed evolution of T cell receptors. He developed the world first human high-affinity soluble TCR, which the affinity for recognizing pHLA was increased by more than one million times as a key breakthrough in the field of TCR. Under his leadership his team has successfully developed a number of high-affinity TCRs at Immunocore in the UK, which has eventually been used in FDA-approved immunotherapy clinical research products. In 2012, he returned to China and led the establishment of China's first high-affinity TCR-mediated T cell therapy platform. The TCR-T product TAEST16001 injection developed by the Xiangxue team has obtained the first TCR-T IND approved by CDE of the National Medical Products Administration.
Lei Zhang
Senior Director, Discovery
Fosun Kite Biotechnology
张雷,中科院生化细胞所博士毕业,在瑞士弗雷德里希生物医学研究所从事博士后研究,加入复星凯特后主持了Yescarta的技术转移落地,和早期临床阶段的CMC管理,目前正在进行全新一代CAR-T细胞药物的研发工作。
Yaqing Zhu
General Manager, CMC
Asclepius Technology Company Group
朱亚青,博士毕业于德国格赖夫斯瓦尔德大学,并在德国联邦动物健康研究所从事研究工作。现任阿思科力(苏州)生物科技有限公司工艺总监,负责公司CAR-NK细胞药物平台各管线产品的工艺转移,中试放大及产业化,并致力于适应现货型细胞治疗产品的新一代工艺开发工作。
Xinpo Jiang
Senior Director of Analytical, Process Validation, QC, QA
Legend Biotech
Dr. Xinpo Jiang, Senior Director of Analytical Department/QA/QC at Legend Biotech, works on development of novel CAR T products in the pipeline. He was CMC Head leading LCAR-B38M CAR T product to clinical trial in China and US (collaborating with Janssen). He was Director of Pharmacology Department at GenScript for assay developments on biologicals and developed many cell-based and biochemical assays, oncology and antibody related functional assays. He received his Doctor of Philosophy from University of Minnesota, Twin Cities. He did a postdoctoral fellowship at Toronto Western Hospital, University of Toronto. Prior to his position at GenScript, Dr. Jiang was a research scientist at NeuroMed Pharmaceuticals. He published around 20 peer-reviewed journal articles and filed around ten patents.
Cheng Liu
Founder and CEO
Eureka Therapeutics
Dr. Cheng Liu is the founder and CEO of Eureka Therapeutics. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a PhD in Molecular Cell Biology from the University of California, Berkeley.
Yu Zhang
SVP & CSO
VCANBIO Cell & Gene Engineering
Dr. Zhang Yu is the SVP&CSO of Vcanbio Cell&Gene Engineering Co.,Ltd (A listed company on Shanghai A stock). Prior to join Aeon, Dr. Zhang was president and CEO of Aeon Therapeutics, a joint-venture biotech company between Eureka Therapeutics Inc. and Vcanbio; assistant president in Vcanbio. Dr. Zhang received his B.S. in Bioengineering and M.S. in Biomedical Engineering from Beihang University, and a Ph.D. in Stem Cell and Regenerative Medicine from Heinrich-Heine-Universität Düsseldorf. In the period of Germany, he worked in Rhine Forum, University of Applied Sciences Bonn-Rhein-Sieg, and was a visiting scholar in German Aerospace Center and University of Palermo. He is a member of German Society of Stem Cell, Chinese Society of Cell Biology, and reviewer of several cell therapy journals, e.g. Current Stem Cell Research&Therapy. Dr. Zhang was the winner of “131 talent plan” and “Tianjin Green Card Plan”.
Xiaowen He
Co-Founder, EVP & CSO
OriginCell Therapeutics
Dr. Peter Xiaowen He has worked on R&D in the fields of immunotherapeutics, vaccine and cell-based products for more than twenty years with 25 patents and over 30 SCI published articles. Dr. He developed the therapeutic Serratia Marcescens formula approved by cFDA as Class I biological product and won the second prize of Science and Technology Progress Award for his development of therapeutic vaccine against hepatocellular carcinoma. Dr. He has been research professor and PIs in Stem Cell Center of New Jersey and Merck USA. Dr. He got a lot of funding from NIH and National Natural Science Foundation of China and led the teams to establish the key manufactory and quality control systems for cell-based therapeutics. Currently Dr. He worked as Co-founder and CSO in Origincell.
Tony Zhang
Chairman & CEO
Wuhan Bio-Raid Biotech
Tong-Cun, Zhang, Ph.D, M.D; a distinguished professor in Hubei Province, is currently the Dean of College of Life Sciences and Health at Wuhan University of Science and Technology(WUST).
Dr. Zhang has got his Ph.D degree in 2000 from Institute of Biophysics, Chinese Academy of Sciences. Dr. Zhang was once honored with the of NRC Postdoctoral Fellowship Award in 2000-2003 in USA and then joined in UNC at Chapel Hill as assistant professor. Since 2012 he has taken a full-time professor and dean in WUST.
Dr. Zhang has aimed to the scientific research of the gene regulation, related to human diseases and development of biological drugs. In recent years, he has focus on CAR-T cell therapy for blood and solid cancers. His team has carried out novel CAR-T clinical trial in several hospitals and got excellent clinical effects and safety, which were published in Blood and Leukemia. CAR-T targeting to CD30 is trialed in clinical phase I.
Dr. Zhang has obtained several grants from The National Natural Science Foundation of China and ministry of Science and Technology, including National Key Research Program, 863 Programs, 973 Program. He has published over 100 theses in relevant research fields at high level scientific Journals. Novel patents for CAR-T cell-therapy over world has been obtained in his leading team.
Since he come back China, Dr. Zhang has been honored with local and national talent and outstanding titles. He was also awarded US-EPA's Scientific and Technological Achievement Award in 2003.
Xingwang Xie
Founder & Chief Executive Officer
Corregene Biotechnology
Dr. XIE got his Master’s degree in Medicine from Peking University and Ph.D in Pathogenic Biology from China CDC. He started his career as a scientist at the Peking University People’s Hospital, Peking University Hepatology Institute, and has devoted over 10 years to studying the genomics and immunobiology of cancer and their clinical implications. Dr. XIE is the founder, chairman and CEO of Corregene. He founded this cell therapy company in 2016, which focused on developing T-cell therapy for solid tumor patients.
Mingjun Wang
Executive President
Shenzhen Institute for Innovation and Translational Medicine
Dr. Mingjun Wang,Executive President of Shenzhen Institute for Innovation and Translational Medicine, received his MD from Anhui Medical University in China and his PhD degree in Cellular Immunology from the University of Copenhagen in Denmark in 2009, and finished his postdoctoral training in cancer immunology at Baylor College of Medicine in Houston of the United States. His research is focused on identification of cancer antigens and the development of T cell-based cancer immunotherapy using TIL, TCR-T cells or CAR-T cells for various types of malignancies. Dr. Mingjun Wang has published more than 30 peer-reviewed papers and three book chapters in the field of cancer immunology.
Huajun Jin
Founder, CEO & CTO
Shanghai Gencells Therapeutics
金华君,博士,研究员。上海君赛生物科技有限公司创始人,CEO/CTO,民建上海市生物医药专委会执行主任。金华君博士拥有丰富的高校、医院、企业的产学研跨界从业经历,深耕肿瘤免疫机制研究和细胞疗法开发十多年,积累大量第一手研发与临床研究经验,熟练掌握细胞新药早期设计、工艺与检测技术开发、临床前研究、临床研究、新药注册申报等全流程。曾开发全球首个自表达抗体的CAR-T细胞治疗实体瘤的临床级技术,以及国内首个基于非病毒载体的CAR-T细胞新药品种,自主建立高效简便的TIL细胞富集培养技术以及转基因TIL细胞治疗方案。主持“重大新药创制”国家科技重大专项项目2项,国家自然科学基金2项,其它省部级课题6项;申请发明专利82项(已授权13项);发表SCI论文30篇(以第一作者或通讯作者发表20篇);曾作为技术端负责人,开展21项细胞免疫治疗项目的临床研究。
Yun Jiang
COO
Beijing Syngentech
Yun Jiang, a member of the Chinese Peasants and Workers Democratic Party, holds a CTU-UIBE MBA and is the winner of the Beijing Science and Technology New Star Program in 2019.
He is now the chairman and COO of Beijing Syngentech Co., Ltd; DGM of Beijing Lotuslake Biomedical Co., Ltd; Secretary General of synthetic biotechnology branch of China Pharmaceutical Biotechnology Association; Deputy Secretary General of liver cancer special committee of Asia Pacific Alliance for diagnosis and treatment of liver diseases.
Beijing SyngenTech Co., Ltd. is a national high-tech enterprise which is committed to using synthetic biology to develop new gene and cell therapy methods for tumor and gene diseases. Synov1.1, the world's first anti-tumor synthetic biotech gene therapy drug, was approved by FDA in 2020.
Yi Jin
Chief Scientific Officer
Genbase Biotechnology
Dr. Yi Jin obtained her Ph.D. degree from Iowa State University and received postdoc training at University of California at Berkeley later. She has 15 years experience on therapeutic biologics discovery and development in Pharmaceutical and Biotech companies in US and China. Worked as project leaders for lead discovery at Bayer (USA), responsible for antibody discovery and novel technology platform. During her tenure, she led multiple projects through different stages of the development, including target discovery and validation on autoimmune disease and cancer immunotherapy. Currently, she serves as Chief Scientific Officers in Shanghai Genbase Biotechnology Co., Ltd.
Daozhan Yu
President and CEO
AAVnerGene
Dr. Daozhan Yu graduated from Molecular Medicine at University of Maryland, School of Medicine. He has been working on several disease models, including diabetes, obesity, cardiovascular disease and neural diseases, for drug screening and gene therapies. He developed a new method to induce brown fat differentiation, which can increase the metabolism and cure obesity and diabetes; He also developed a new peptide drug for cardiovascular diseases that are a first-in-class drug in preclinical stage; Dr. Yu first established the iPSC model for Niemann-Pick disease and screened a small molecule, which are at phase III clinical trial.
Recently, Dr. Yu has been focusing on AAV mediated gene therapy. He worked as scientist at AAV gene therapy expert’s lab and led the virus production department as director in a renowned industrial company. In 2019, he founded AAVnerGene developing new technologies to solve bottleneck problems for AAV gene therapy. AAVnerGene has established the AAV capsid screening platform and is emerging as a game changer for next generation of AAV gene therapy.
Wen Wang
Chief Medical Officer
IASO Biotherapeutics
Dr. Wen (Maxwell) Wang currently is the Chief Medical Officer in IASO Biotherapeutics Co., Ltd. He obtained his M.D. degree in Wuerzburg University in Germany and Ph.D. degree from University of Aberdeen in UK and then did his postdoctoral training in at UConn Health Center in USA.
Dr. Wang has over 7 years of experience in Chinese Leading cell therapy companies including JW Therapeutics, Cellular Biomedicine Group (Nasdaq: CBMG) in clinical, preclinical, and translational development including CART cell and stem cell therapy. He held one of leading position in the 1st Chinese CD19-targeted CART cell and Mesenchymal Stem Cell INDs.
Before industry career, Dr. Wang worked as a Resident and Attending in Orthopedic Department in Shanghai TCM Hospital for 5 years.
Sun Yan
Vice President, General Manager, Cell Drug Business Unit
Shanghai Cell Therapy Group
孙艳,上海细胞治疗集团副总裁,细胞药物BU总经理,主要从事CAR-T细胞药物开发及相关管理工作。带领团队完成国内首个非病毒载体CAR-T细胞药物的研究及注册申报,获得临床试验许可。
Wei Wang
Vice President, Clinical Development
CARsgen Therapeutics
Dr. Wei Wang is the Vice President of Clinical Development at CARsgen. She leads CAR-T and monoclonal antibodies China clinical development programs and manages medical affairs, clinical operation, biometrics and pharmacovigilance.
She has over a decade experiences in China and global clinical development programs in Merck, Novartis and Pfizer, managing team in clinical development, medical affairs and pharmacovigilance. Dr. Wei Wang worked as the practicing pediatric physician for 6 years in Xiangya Hospital of Central South University. She earned her Master degree in clinical medicine from Central South University, and the M.D. & Ph.D. degree from Fudan University.
Xueqiang Zhao
CEO & Co-Founder
China Immunotech
Dr. Xueqiang Zhao is the CEO and co-founder of China Immunotech (Beijing) Biotechnology Co. Ltd. He received his PhD degree in tumor immunology from Chinese Academy of Sciences, and got his postdoctoral training in MD Anderson Cancer Center, studying the activation of T cells. In 2014, he joined Tsinghua University as an associate professor, working on genetically engineered T cells for cancer immunotherapy. Dr. Zhao has more than 15 years’ experience in tumor immunology and has 20 patents on CAR-T and TCR-T therapies, and over 30 peer-reviewed publications. Currently, he is a co-founder of China Immunotech, which pioneered the innovative TCR-based STAR technology. The STAR-T cell therapy combines the advantages of TCR-T and CAR-T cell therapies, exhibiting HLA-independent killing of tumor cells and generating low CRS effects in clinical trials. The STAR-T therapy has done clinical trials in 30 patients with hematological malignancies, which were reported by the 2020 ASH and will be presented on EHA meeting next month. And The effects of STAR-T cells on treating solid tumors were published by Science Translational Medicine in March, 2021.
Pamela Yin
Application Development Manager of China Region
Colder Products Company
Pamela Yin, is the Application Development Manager of China region in CPC. Pamela has 10+ years’ experience of Application and Technical role in Pharmaceutical and Biotech industries, including the past 7 years focusing on single use technology in Bioprocessing. Her expertise is helping CPC to develop connection technology that support pharmaceutical customers to find the best connection solution with single-use technology.
Crystal Sun
Chairman & CEO
Shanghai Immunohead biotech.
清华大学肿瘤药理学硕士,复旦大学药理学博士生。具有十几年药品法规注册和研发项目管理经验,多年创业型生物医药企业工作经验。2017年初加入上海复星凯特生物科技有限公司担任总裁助理兼药政注册及公共事务总监,推动细胞治疗政策法规建立和中国第一个CAR-T的NDA申报。曾任上海医药质量协会细胞治疗专委会秘书长。此前,在复宏汉霖申报10了中国IND和2个双报项目,推动中国的生物类似药的法规其并推动中国第一个BiosimilarNDA批准上市。
Master Degree of Tumor Pharmacology, graduated from Tsinghua University. She has more than 10 years drug registration, regulatory affair and project management experience.
Crystal Sun joined Fosun Kite biotechnology company in early 2017, served as CEO assistant and director of regulatory affairs and government affair. She promoted the establishment of Development and Review Guideline of CAR-T cell Therapy in China and makes great effort to standardize commercialization of CAR-T cell-therapy product, following the pathway of drug registration. She also taked in charge of FKC876 NDA application as a first CAR-T in China.
Prior to join Fosun Kite, she was in charge of the department of drug registration in Shanghai Henlius Biotech, Inc, registered 10 IND projects in China and 2 projects both in China and Europe. These projects have all been approved for clinical trial. Crystal Sun has been dedicated to promoting establishment of Biosimilar Guideline in China. Anti-CD20 mAb, Rituximab of Henlius, has been approved NDA as a first Biosimilar in China.
Huimin Meng
Medical Director
PersonGen BioTherapeutics
孟会敏,MD & PhD,于潍坊医学院护理学专业毕业,获得医学学士学位;于南方医科大学病理学专业毕业,获得医学硕士学位;于苏州大学唐仲英医学研究院血液学研究中心毕业,获得医学博士学位。2012年曾赴美国休斯敦Apocell公司接受CTC技术培训。现任博生吉博生吉医药科技(苏州)有限公司高级医学官。 孟会敏博士在攻读博士学位期间,接受了系统的CAR-T细胞免疫治疗技术与临床转化应用的系统培训;负责博生吉CAR-T临床试验方案的开发与撰写,领导与协调和各个临床研究机构的合作、推动和管理了多项CAR-T的临床试验项目,涵盖血液瘤和实体肿瘤,其中包括博生吉自主开发的First-in-class CART细胞药物的临床试验,为博生吉这些项目的顺利进行提供了强有力的保障。
陈苗苗
高级项目经理
上海(南翔)精准医学产业园
陈苗苗,现任高级项目经理,负责上海(南翔)精准医学产业园招商、项目引进、政策对接和融资服务等工作。2019年毕业后加入复旦大学宁波研究院,接触到的项目近800余家,落户服务项目20家,针对项目需求给出不同的解决方案,最终达到双赢的目标。从项目选址到最终项目入驻全部一手服务。
路伟振
层析产品技术支持
赛多利斯
毕业于哈尔滨工业大学获得生物化学与分子生物学硕士学位,于2018年加入赛多利斯,负责下游过滤产品技术支持工作,后加入赛多利斯中国层析团队,专注层析产品在中国的推广和支持。在此之前,他曾就职于上海药明生物技术有限公司做下游纯化工作。
章康健
联合创始人,董事兼总经理
元宋生物
中国科学院上海生化与细胞所生物化学与分子生物学博士,师从中科院刘新垣院士。中科院生化与细胞所副研究员,宾夕法尼亚大学访问学者。目前主要从事癌症的靶向基因-病毒抗癌策略的科研产业化,担任上海元宋生物技术有限公司联合创始人,董事兼总经理。主持过国家自然科学院基金1项,四川省科技厅技术创新工程专项基金1项,上海市科技型中小企业技术创新资金3项,上海市2019年度科技创新行动计划生物医药领域科技支撑项目1项,作为骨干还参与过多项国家科技部及中科院系统科研资助项目。同时作为发明人参与靶向基因-病毒抗癌专利申请13项,参与编写一部癌症研究学术专著1部,为国际细胞因子与干扰素学会会员,荣获过中国第三届“《中国细胞生物学学报》—Cell Signaling Technology细胞生物学科研新秀奖”、中科院上海生化与细胞所多次年度优秀员工,上海奉贤区第二届滨海青年英才,上海奉贤区滨海贤人拔尖人才系列等荣誉。曾与合作单位制药公司开展过对正在美国、新加坡开展临床试验的某生物I类新药抗癌临床转化研究工作。在国内外知名学术期刊如Clinical Cancer Research, Human Gene Therapy, GeneTherapy, Cancer Gene Therapy, Protein Cell等发表专业学术论文38篇,并担任多家国内外专业期刊的特邀审稿人。
作为药物研发初创公司创始人兼CEO,熟悉职能部门内控管理和团队建设,人力资源管理,科研项目精细化管理,竞业科研情报数据信息化系统研发与构建,从科研基础研发到新药临床转化,商务拓展具有实战经验。带领团队参加第七届全国创新创业大赛总决赛,荣获“国家优秀企业”称号,同时使企业先后获得“高新技术企业”和“知识产权贯标认证”、“星耀榜-2020中国生物医药最具创新力企业50强”、“2020上海最具投资潜力50强创业企业”等多项资质与荣誉。是一名溶瘤病毒抗癌药物科研产业化积极践行者!
Robin Zhang
Vice President
HuiGene Therapeutics
张瑜博士是辉大基因副总裁,负责对外合作和产品授权。在加入辉大基因之前张博士担任天士力生物副总裁兼执行董事。通过张博士的投资和对外合作,成功的把一家传统的中药企业带进了全球医药企业的朋友圈。加入天士力之前,张博士曾服务于辉瑞,拜耳,IMS,艾尔弗雷德曼基金会和瑞银等全球机构,负责包括并购,产品引进及外包,新产品上市,中国市场战略,产品销售,新产品研发及证券投研。在处方药,细胞治疗,OTC及保健品,可植入医疗器械方面积累了丰富的经验。
张博士毕业于北京医科大学,在北大医院完成了骨科住院医师培训。在美国罗切斯特大学同时获得了病理学博士学位及健康科学管理与金融工商管理硕士学位。
Dr. Zhang is Vice President of HuiGene Therapeutics and responsible for licensing and external collaboration. He has over 15 years working experience in healthcare industry in both China and US. Before joined HuiGene, Dr. Zhang worked as Executive Director & Vice President at Tasly Biopharmaceuticals. Through his efforts, Dr. Zhang successfully brought a traditional Chinese medicine company into the friend circle of global biopharmaceutical enterprises. Prior Tasly, Dr. Zhang served several positions in Pfizer, Bayer, IMS, Alfred Mann Foundation, and UBS with different responsibilities including M&A, license-in/out, new product launch, China strategy, sales and marketing, product development, and equity research. He has built solid experience in prescription drugs, cell therapy, OTC/nutrition supplement, and implantable medical device.
Dr. Zhang graduated from Beijing Medical University and finished his orthopedic resident training in Peking University First Hospital. He received both PhD of Pathology and MBA of Health Science Management & Finance from University of Rochester.
Li-Feng Zhang
R&D Director
TCRCure Biopharma
Dr. Li-Feng Zhang is the R&D Director of TCRCure Biopharma. He received his Ph.D. degree in Molecular Genetics from Baylor University in 2002, and completed his postdoc research at Harvard Medical School in 2008. He joined Nanyang Technological University in Singapore as an assistant professor in 2009. His research is focused on epigenetic regulation of gene expression and genetic engineering of the mammalian genome. Dr. Zhang joined TCRCure in 2020. He is supervising the development of multiple immune cell therapy products targeting solid tumors, including TCR-T, CAR-T and CAR-NK.
George Zhou
Chairman & CEO
Joint Biosciences
22年新药研发和投资的丰富经验;成功地创立和管理过3家新药开发和制药公司,并担任CEO 、董事长和CSO;主持投资或并购过中国和美国20多家新药开发和制药企业, 其中7家上市公司;
Over 22-years experiences in Biotech & Pharmaceuticals in US.,Mainland, Hong Kong of China;Co-Founder & CEO for 3 Biotech Companies and sold two of them; Invested over 20 biotech companies, 14 in US. 7 of all have completed IPO.
Honglin Xie
Application Director
Kactus Biosystems
谢宏林,恺佧生物科技(上海)有限公司客户应用总监,专注于生物医药领域酶/因子/蛋白等原料的需求。此前就职于abcam和金斯瑞从事了10年的抗体发现工作,主导了上千个科研,诊断,药物抗体的研发。
Changfeng Zhang
Associate Director, Dept of Cell Therapy
Livzon Biotech
Dr. Changfeng Zhang is the associate director of the Department of Cell Therapy, Livzon Biotech, with expertise in CMC, clinical applications and regulatory affairs of CART cells. He was one of the core members of Dr. Carl June’s team responsible for translational study and process development. After returning to China, Dr. Zhang started working as the RA director of UniCar Therapy, Ltd., China, and achieved the first IND approval of a gene-modified CART product in China.
Dr. Zhang has 8 publications in top-ranked journals such as Nature Medicine, Blood and etc., and was awarded the High-level Talent prizes of the cities of Shenzhen, Zhuhai, Suzhou and Nanchang. Additionally, he established academic collaborations with the Chinese FDA, NICPBP and several regulatory agencies by introducing world-famous CART therapist such as Dr. Stephan Grupp and Dr. Joseph Melenhorst, which greatly facilitated the policy development of CART therapy in China.
Speaker Bio
Li Chen
Founder and CEO
Hua Medicine
•陈力,华领医药技术(上海)有限公司董事长、首席执行官、创始人、首席科学官。
•1992年获得Lowa州立大学哲学博士,同年加入罗氏美国研发中心,历任项目主管、高通量技术部主任,全球化学管理委员会成员,罗氏中国研发中心首席科学官,拥有20多年新药研发创新及管理经验。
•曾任同济大学生命科学院兼职教授、博士研究生导师,中科院上海药物所兼职研究员。
•曾任美中药协主席,为促进中美新药研发领域的交流合作发挥了重要作用,并为促进国家MAH等重大制度突破做出了重大贡献。
•陈力博士于2011创建华领医药,2018年香港主板上市。
•是43件授权发明专利和127件发明专利申请的发明人, 并发表60多篇科学论文,包括在Lancet Diabetes and Endocrinology, Diabetes, Obesity and Metabolisms, J Diabetes Res., Clinical Pharmacokinetics, PNAS, J Med Chem, J Am Chem Soc, J. Org Chem等著名国际刊物。
Ming Guo
President & COO, Co-Founder
Ascentage Pharma
Dr. Guo has been working in the healthcare industry since 1991, including Pfizer, Ascenta Therapeutics, and Ascentage Pharma. At Pfizer (1995-2005) with various technical and management roles, Dr. Guo participated in many NCE drug R&D projects, several of which have successfully reached commercial stages. At Ascenta (2005-2009), Dr. Guo was the founding Vice President of Pharmaceutical Sciences & Manufacturing, and also General Manager of Ascenta (Shanghai) R&D Center which is likely the first company engaged in global NCE drug R&D in China from 2005. Dr. Guo played an important role in Ascenta’s >$600M global out-licensing deals (i.e., with Sanofi-Aventis in 2010 and with Debio in 2011). Based on Ascenta (Shanghai) team, Dr. Guo co-founded Ascentage Pharma in September 2009, a globally positioned China innovative NCE drug R&D company, and currently serves as President & COO. The company has quickly built up a pipeline of 8 clinical-stage NCE projects along with several IND-enabling and discovery stage projects, covering oncology and anti-viral / anti-aging therapeutic areas through its apoptosis/PPI platform. Ascentage Pharma had a successful IPO at Hong Kong Stock Exchange in 2019. During 2002-2005, Dr. Guo served as an Overseas Advisor for Beijing Zhongguangcun Biotech Park in China. He has been an adjunct professor, a faculty and graduate student adviser for the IPEM program at Peking University during 2007-2018. Dr. Guo served as an Independent Board Director at Porton Corporation (Chongqing, China) during 2012-2016, overseeing its successful IPO at Shengzhen Exchange, China, in 2014. As a co-founder and the founding Chairman, Dr. Guo has served on Board of Directors of SABPA (www.sabpa.org). Dr. Guo received his Ph.D. degree in Organic Chemistry at the University of California at San Diego; M.Sc. in Medicinal Chemistry at Institute of Materia Medica, Chinese Academy of Sciences; and B.S. in Chemistry at Peking Normal University.
James Yan
Chief Operating Officer, R&D
Zai Lab
James Yan, Ph.D., has been our Chief Operating Officer, R&D since April 2020. Prior to this role, he was the Executive Vice President and Head of Pre-Clinical Development and Program & Portfolio Management. Prior to joining Zai Lab, Dr. Yan was the head of the Covance early development Shanghai site, where he was responsible for all aspects of the business. Between 2009 and 2012, Dr. Yan served as the head of drug safety evaluation and program management of Hutchison Medi-Pharma. Prior to Hutchison Medi-Pharma, Dr. Yan had significant experience at Pfizer in the United States. Over the course of his career, Dr. Yan was involved in many IND and NDA filings for multiple drug candidates and gained substantial experience working with regulatory agencies in several countries.
Dr. Yan holds a Ph.D. from Peking Union Medical University and completed post-doctoral training at the University of Chicago’s Ben-May Institute for Cancer Research. He is a diplomat of the American Board of Toxicology (DABT), a council member of the China Society of Toxicology and a member of the Drug Toxicity and Drug Safety Evaluation Committee, a member of Pharmaceutical Toxicology Committee of China Pharmacology Society and vice chairman of Drug R&D Committee of China Pharmaceutical Innovation and Research Association (PhIRDA).
阎水忠博士自2020年4月起担任再鼎医药研究及开发首席运营官。在此之前,他曾任再鼎医药执行副总裁,负责早期研发及项目和产品组合管理。加入再鼎之前,阎水忠博士是科文斯早期开发上海研发中心负责人,负责各个方面的业务。2009年至2012年期间,阎水忠博士是和记黄埔医药公司药物安全性评价和项目管理负责人。加入和记黄埔医药之前,阎水忠博士在美国辉瑞积累了丰富的经验。在其职业生涯中,阎水忠博士参与过多个候选药物的IND和NDA申请工作,积累起与数个国家的卫生监管机构合作的丰富经验。
阎水忠博士拥有北京协和医科大学博士学位,并在芝加哥大学Ben-May癌症研究所完成博士后研究。阎水忠博士是美国毒理学会认证专家、中国毒理协会理事会理事、药物毒理与安全性评价专业委员会委员、中国药理学会药物毒理专业委员会委员及中国医药创新促进会药物研发专业委员会副主任委员。
尹鹤群
副总裁兼创新药物研究院院长
齐鲁制药集团
尹鹤群, 齐鲁制药集团副总裁兼创新药物研究院院长, 曾任辉瑞全球研发副总裁(美国),诺华研发执行总监(美国,中国),复星医药中央研究院院长. 领导了包括美国,中国,欧洲在内的全球性的研发团队,并在美国培养了多名博士后。为十多个新药的成功研发上市作出了重要贡献,其中包括全世界第一个CAR-T疗法Kymriah, 首个IL17抗体Cosentyx,突破性心衰药Entresto ,重磅肿瘤药Affinitor 和抗乙肝药Telbivudine. 早年就学于北京大学(化学学士),中科院(化学硕士),University of Rochester (药理学博士),University of California at San Francisco (生物学博士后),Fairleigh Dickinson University (MBA 课程)。全球性的经验涵盖了全研发链,包括早期研究发现,后期全球开发及注册报批。
Weicheng Zhou
Director, State Key Lab of New Drug and Pharmaceutical Process
Shanghai Institute of Pharmaceutical Industry
周伟澄,博士,荣获“第四届中国青年科技奖”,“国家级有突出贡献的中青年科技专家”,“上海市优秀学科带头人”和“上海市领军人才”等称号。享受国务院特殊津贴。上海医药工业研究院研究员,博士研究生导师,《中国医药工业杂志》总编辑。上海交通大学药学院兼职教授,复旦大学药学院博士生导师。曾任创新药物与制药工艺国家重点实验室主任,上海市抗感染药物重点实验室主任。研究课题多次受到联合国开发署/世界银行/世界卫生组织、国家科技攻关项目、国家重大新药创制、国家973项目等的资助。获CFDA的一类新药证书一份,其他类别新药证书6份。国家授权专利60多项。主编《高等药物化学选论)》和《化学药物制备的工业化技术》两本研究生教科书,化学工业出版社出版。发表论文180多篇,培养博士研究生(已毕业)21人,硕士研究生37人。
丁红霞
首席执行官
药渡
丁红霞,博士,药物化学专业,毕业于浙江大学和中科院上海药物研究所,拥有12年以上创新药物研发项目工作经验。2013年,联合创办Pharmacodia (药渡)并担任CEO,专注于打造以大数据驱动的生物医药研发垂直领域“第一”决策型信息平台。 在创办药渡之前,曾任Shenogen(珅奥基医药)化学部高级研发总监, BioDuro(保诺科技)资深组长,参与多个国际性的化学-生物整合研发项目。在过去的8年中,特邀撰写全球每年上市新药综述文章《Synthetic Approaches to Year’s New Drugs》,发表于“Journal of Medicinal Chemistry”,“Bioorganic & Medicinal Chemistry”等杂志,是该杂志中下载量最高的期刊文章之一。
Dr. Ding is the co-founder and Chief Executive Officer of Pharmacodia, which is the leading pharmaceutical big data company in China. Dr. Ding obtained Ph.D degree in Medicinal Chemistry from Zhejiang University in 2006, and have more than 12 years experiences in drug discovery and development with strong leadership in project management. Prior to found Pharmacodia, she worked at Shenogen Pharma Group, a China-based Biotech company, as senior director of R&D department. Prior to join Shenogen, she worked at BioDuro as senior group leader. Dr. Ding also is the key contributor for the annual review paper “Synthetic Approaches to Year’s New Drugs”, which is published in “Journal of Medicinal Chemistry”. The article is very well received by the community and is the most downloaded article of the journal each year.
陈洪
副总经理,研发中心总经理
成都苑东生物制药股份有限公司
现任成都苑东生物制药股份有限公司副总经理,研发中心总经理。河北省“百人计划”医药专家和外专局特聘专家。以及四川省“千人计划”医药专家。他1996年获得美国Cleveland State University分析化学博士学位。之后又在全球心脏方面最著名的Cleveland Clinic Foundation 做了两年生物医药博士后研究。拥有25年在美国Adolor、J&J、Teva和Nexgen Pharma和以岭药业丰富的工作和管理经历;曾担任过全球最大仿制药公司Teva的分析和技术服务总监以及美国Nexgen Pharma的研发总监和高级总监,以岭研究院副院长。亲自领导和参与30多个新药和仿制药的研发,其中一个一类新药(Entereg)和17个ANDA固体和液体制剂产品获得美国FDA批准和3个固体一致性评价获得中国CDE批准上市。现负责苑东生物创新药,改良型新药和仿制药研发和国际制剂注册申报.有着丰富的团队建设、项目管理、国际认证、研发质量体系建立、制剂注册申报的经验。曾经出版,演讲和展示了113篇在药物研发,生物医学方面的科学论文。
Dr. Chen is currently the Vice President of Easton Biopharmaceuticals and the President of the R&D Center. He has been honored the "Hundred/Thousand Talents Program" medical expert by both Hubei and Sichuan Province. He received his Ph.D. in analytical chemistry from Cleveland State University in 1996. He then spent two years in biomedical postdoctoral research at the Cleveland Clinic Foundation, the world's most famous cardiology clinic center. He has 25 years of working and management experience in Adolor, J&J, Teva and Nexgen Pharma in the United States and Yiling, Easton Pharma in China. He has served as Director of Analytical and Technical Services of Teva, the world's largest generics company, and R&D Director and Senior Director of Nexgen Pharma, USA, R&D Vice President of Yiling Pharma. Directly led and participated in the development of more than 30 new drugs and generics, including a Class 1 new drug (Entereg), 15 ANDA solid and liquid products approved by the US FDA and 3 products approved through Consistency evaluation by China CDE. He is responsible for the research and development of new,505b2, generic drugs and ANDA registration of Easton Biopharmaceutical。 Dr. Chen has extensive experience in team building, project management, GMP certification, establishment of R&D quality system and ANDA filings. He has published, lectured and presented more than 113 scientific papers in drug discovery and biomedical science.
边峰
高级总监/新兴科学与创新合作负责人 (中国)
辉瑞全球研发
Dr. Feng Bian is a Senior Director and China Emerging Science Lead in Pfizer Emerging Science & Innovation (ES&I) of Pfizer Worldwide Research, Development & Medical. She is based in Shanghai and responsible for cultivating strong and in-depth scientific relationships with Academic and Life Science Communities with a primary focus on China and nearby regions to access emerging sciences including novel targets, promising preclinical assets, and breakthrough technologies.
Prior to ES&I, Dr. Bian was a senior investigator in China Novartis Institutes for Biomedical Research and group head of liver pharmacology since 2014 in Shanghai. At Novartis, she was a project leader and managed liver disease pharmacology platform to deliver data packages for worldwide drug discovery projects. Before Novartis, she was a key scientist participated in setting up JnJ China research labs in 2012, and Associate Director of Biology to manage CROs and academic collaborations as well as internal R&D programs. Dr. Bian began her R&D career in Parke-Davis/Warner-Lambert in US as an in vivo pharmacologist in the Neuroscience Division, and later became a principle scientist in Pfizer’s Neurodegeneration and Psychotherapeutics Unit, contributing to programs like Lyrica, discovery programs for Alzheimer’s disease, bipolar depression and dermal fibrosis. Dr. Bian has 20 years of expertise in small molecule and biologics drug discovery and her work has enabled several NMEs to reach first in human. Dr. Bian received her Doctorate degree in Biochemistry from The Ohio State University and her Bachelor of Science degree from Nankai University at Tianjin, China
任国宾
特聘教授,副院长
华东理工大学
任国宾,华东理工大学特聘教授、副院长、博士生导师、国家食品药品监督管理局药品注册审评专家咨询委员会委员、教育部高等学校药学类专业教学指导委员会制药工程专业教学指导分委员会副秘书长、中国药学会制药工程专委会副主任委员、中国晶体学会理事。分别于1997年、2002年、2005年取得学士、硕士、博士学位;曾供职于苏州诺华制药科技有限公司、诺华(中国)生物医学有限公司及上海医药工业研究院;2013年7月加入华东理工大学。任国宾教授近年来一直从事药物晶体工程技术研究,基于新型药物晶体预测技术和外源物理场诱导进行药物固体形态研究,分别与浙江海正药业股份有限公司等医药企业合作,成功完成逾50个药物品种的系统固态化学研究,突破原研专利壁垒并形成自有知识产权;基于相变前超分子组装调控以及晶核微环境控制的理念,与浙江华海药业股份有限公司等制药企业合作,成功实现近20个药物品种结晶技术产业化开发和技术转移,近3年产值逾15亿元。近年来承担国家自然科学基金面上项目3项;发表论文50余篇,获授权专利22项。分别获得上海市科技进步二等奖、中国产学研合作创新奖、第十三届中国专利优秀奖。
谢沐风
副主任药师
上海市食品药品检验所
1990年~1995年 沈阳药科大学 日语药学专业本科毕业
1995年~1998年 沈阳药科大学 药物分析专业硕士研究生毕业
1998年~至今 上海市食品药品检验所工作 专业职称:副主任药师
主要从事化学药品的仿制药复核、药典起草、进口药品质量标准复核、现场考核和质量标准制订等工作。
2003年8月 ~ 2004年2月
赴日本国立医药品食品卫生研究所(即国家药品检验所)药品部进修。
详细了解了发达国家对于药品的审评要点与技术要求;师从《日本药品品质再评价工程(即仿制药质量一致性评价)》“总设计师”系统学习了实施细节与技术应用,掌握了“如何采用多条特征溶出曲线评价口服固体制剂品质”方法与手段,深刻了解了溶出度试验对于仿制药的重大意义和举足轻重的作用,以及发达国家如何提高和控制药品内在品质的具体措施与手段。
截止目前,发表了80多篇药品品质评价方法的思路类文章,尤多篇溶出度和有关物质研究文章引起业内瞩目。
2007年1月 曾担任国家发改委价格司药品价格处顾问。
2008年起~至今 担任国家药品监督局高级培训学院、全国医药技术市场协会等“化学药品质量研究”授课教师。
2009年1月、在国内知名的药学网站——丁香园创立“溶出度研究”专栏,登载了撰写的10多万字相关内容。
2009年~2012年 任国家食品药品监督管理局市场监督办公室专家顾问 负责指导“全国评价性抽验工作”,并首次全面引入了“如何利用体外多条溶出曲线评价口服固体制剂内在品质”的作法,发现了部分国产上市品体外多条溶出曲线与原研品的显著性差异,从而为临床疗效和毒副作用上的差距提供了佐证,为2012年初国家推出“仿制药质量与疗效一致性评价工作”奠定了基础。
2010年 曾担任国家药品审评中心顾问,主持编译了《日本橙皮书——多条溶出曲线数据库》和《日本仿制药生物等效性试验系列指导原则》等。
2012年6月~2013年10月 担任《国家仿制药一致性评价项目》办公室专家,参与起草了《如何测定原研制剂多条特征溶出曲线指导原则》、《如何进行仿制品与原研品多条溶出曲线比较指导原则》和具体品种比较法。
2013年12月 在国内知名药学网站——丁香园创立“杂质研究与品质评价”专栏,登载了撰写的10多万字相关内容。截止目前,溶出度专栏和杂质专栏的内容已成为国内研发人员的《必读手册》。
担任《中国医药工业杂志》、《药品评价(医院药学版)杂志》编委
Steven Hu
Chief Technology Officer
Everest Medicines
Dr. Steven Hu currently is the Senior Vice President of Everest Medicines, being responsible for CMC and supply chain. Before he was the Senior Director of CMC in Roche Pharm Research and Development (pRED) Shanghai, heading process research and synthesis, analytical, preformulation and formulation development to support Roche China portfolio. Before joining Roche, Steven was the Director of New Product Development (NPD) of GSK China R&D, overseeing the whole drug product development life cycle from formulation development and optimization, process development and scale-up to technology transfer to commercial manufacturing. Steven had worked in Merck (West Point, PA) and J&J (Spring House, PA) respectively in the United States before coming back China in 2010.
Steven obtained his Ph.D. in Chemical Engineering from Brown University, USA, and then spent about two years at MIT as a Post-doctoral Research Fellow.
Shuguang Hou
Chairman and CEO
Sichuan Purity Pharmaceutical
侯曙光博士,教授,博士生导师,教授级高级工程师,国务院政府特殊津贴专家,四川普锐特药业有限公司董事长、总经理;成都中医药大学首席教授,中国颗粒学会吸入颗粒专业委员会副主任委员,中国药理学会临床药理委员会委员,中国卫生经济学会药物政策专委会委员,全国吸入给药联盟副主席;四川省和成都市特聘专家,四川省学术和技术带头人。1991年获北京医科大学(现北京大学医学部)药学专业学士学位,2001年获美国Virginia Commonwealth University 博士学位,历任美国PPD公司研究员、美国3M公司资深研究专家和亚太区市场技术部经理等职务。2012年回国,创建了集研发和生产于一体的普锐特药业有限公司, 建立了新型吸入药物递送研发平台和cGMP标准生产基地。公司在研品种30余个,已申报产品20余个,获得临床批件13个,生产批件4个。发表学术文章21篇,获得专利10项,参与编写和翻译学术专著2部。曾获美国3M公司全球营销卓越奖,美国Virginia Commonwealth University“John Wood Award”奖,美国学术界药学会“Rho Chi”荣誉奖和美国“Phi Kappa Phi”奖。
Fred Ouyang
Senior Vice President, R&D
MingMed Biotechnology
欧阳晖博士是广州因明生物的资深研发副总裁。欧阳博士2003-2014年在世界500强的跨国公司艾尔健和福泰制药工作,负责给药系统的药代动力学研究和安全评估,支持给药系统的药剂学创新改造,参与领导多个项目从临床前研究到生产批文申报的全过程,参与的项目Ozurdex和® Trivaris®(治疗黄斑病变的长效眼底注射药物)均获FDA批准上市。2014年担任艾伦实验室运营总监,从事仿制药和剂型改良药的研发,负责公司日常运营,人员管理,项目融资,战略合作,制定并实施公司发展计划。2020年加入因明生物,从事First-In-Class眼科,肿瘤免疫,医美药物的研发。欧阳博士发表学术论文20余篇,持有多个眼科药物和新型给药系统发明专利。曾担任中美生物医药协会洛杉矶分会会长和董事会董事,获得北京大学药学院学士,协和药物研究所药物化学硕士,美国北卡罗莱那州教堂山分校药学博士,美国加州大学洛杉矶分校工商管理硕士。
Jin She
Senior Vice President, CMC
Hua Medicine
佘劲 博士,高级副总裁,药物研发生产部
佘劲博士在华领医药领导药物研发生产部,负责原料药和制剂产品的研发,生产和供应管理。佘博士在中美两国的生物科技公司与大型跨国制药公司有十七年以上的工作经验。加入华领之前,曾在默沙东中国研发中心担任过工艺化学研发总监,并曾在罗氏中国研发中心担任化学工艺研究与合成部门的主管。佘博士还曾就职于美国Inspire制药公司,担任高级研究员并负责领导化学工艺研究团队。佘劲博士本科和硕士研究生毕业于北京大学,并在美国北卡罗来纳大学获得了有机化学博士学位。佘博士发表过多篇学术论文和发明专利,现在担任华东理工大学工程硕士项目的工业界导师。
Shih-Ying Chang
Vice President and CMC Head
Dizal Pharmaceutical
Shih-Ying joined Dizal at January 2019 as the CMC head for API and drug products development, Clinical manufacturing, and supply chain management. Before coming back to Shanghai, he has worked in Pharmaceutical Development in Bristol-Myers Squibb at New Brunswick New Jersey for 13 years. During the tenure in BMS, he has worked on more than 40 different new chemical entities including Brivanib and Cabozentinib in the oncology area, contributed more than 5 NDA dossiers preparation, especially as the author of the Module 3 QbD sections for Onglyza, which was approved as the first QbD-based NDA filings. Other approved NDAs that he has participated including Sprycel, Kombiglyza, Reyataz, and Daclatasvir. After coming back to Shanghai to join Hutchison MediPharma as the Executive Director of Formulation at 2015, he has contributed to Fruquintinib NDA approval in CFDA. He has also served as the CMC project lead to collaborate with AstraZeneca for the joint global development of Savolitib. In Hutchison he successfully finished two bio-equivalency studies to facilitate formulation changes during pivotal trials.
Bo Liu
Vice President of Process Research & Development
Hutchison MediPharma
1995年于兰州大学获有机化学博士学位。之后在美国德州理工大学、纽约州立大学等学校进行了多年博士后研究工作。从2002年起在加拿大多伦多的Toronto Research Chemicals, Apotex Inc.等公司担任资深化学家。于2008年回国加入上海睿智化学,从事工艺研发和放大生产等CMC相关工作。2012年加入和记黄埔医药(上海)有限公司药学部,负责原料药工艺的研发和生产,期间经历了多个项目的临床申报和NDA申报。
Xi Chen
Senior Vice President of Process R&D
Shenogen Pharma Group
After Obtained his Ph.D. from Purdue University, Dr. Chen joined Department of Process R&D in Gilead Sciences Inc., and was responsible for process optimization, tech transfer and commercial manufacturing. He participated in many Gilead’s blockbuster projects, such as Viread, Emtriva, Hepsera, Truvada and Atripla. The combined sales of these products in 2012 exceeded 35 billion dollars.
Starting from 2009, Dr. Chen held several executive positions for some pharmaceutical companies, including Process Director in WuXi AppTec Co., Ltd., Vice President of API division in Huahai Pharmaceutical Co., Ltd., Executive Vice President in Tibet Rhodiola Pharmaceutical Holding Co., President in Zhongke Biopharma Co., Ltd. Dr. Chen has 22 years pharmaceutical experiences in USA and China. His specialty is in areas of CMC and drug substance manufacturing. He has managed a wide range of projects, including API manufacturing, GMP appliances, formulation development, facility construction and supply chain management.
Chutian Shu
Chief Technology Officer
Alebund Pharmaceuticals
舒楚天博士,现任上海礼邦医药科技有限公司CTO,负责公司早期研发,CMC及商业化生产(筹划中)。于中国科技大学获得学士学位后赴美攻读获Emory大学化学博士学位,并在美国耶鲁大学从事博士后研究。在加入礼邦之前曾先后担任上海拓臻医药科技有限公司CMC负责人,苏州诺华制药科技有限公司化学工艺部项目负责人兼团队主管,山东轩竹医药科技有限公司化学兼CMC副总裁,勃林格-英格翰制药公司美国研发中心化学工艺部首席科学家。负责并主持了超过十个进入临床阶段的创新药CMC研发,在国际顶级学术期刊上发表过多篇学术论文,获勃林格-英格翰公司总裁奖,并受聘山东省泰山学者海外特聘专家。
Yang Gao
Director, Head of Suzhou Analytical Research and Development
BeiGene
高阳博士担任百济神州苏州分析研发负责人,主管百济神州研发管线中所有小分子项目的质量研究和上市申报工作。在加入百济神州之前,曾先后就职于科文斯(Covance)和吉利德科学(Gilead Sciences),参与和领导了了多个临床和商业化阶段产品的质量研究和上市申报。高阳博士本科毕业于北京大学,博士毕业于美国普渡大学,研究专注于使用高分辨质谱解决复杂生物大分子的表征和结构解析等问题。
Dr. Yang Gao is the Head of Suzhou Analytical Research and Development at BeiGene, responsible for quality control strategy and market application for all small molecule pipelines. Prior to BeiGene, Yang has worked at Covance and Gilead Sciences in the US, he participated and led multiple clinical and commercial stage product development and market applications. Yang has a B.S. from Peking University, and Ph.D. from Purdue University, his graduate research focused on macro-biomolecular characterization and structure elucidation using high resolution mass spectrometry.
Bo Shan
Vice President, Discovery and Early development
Antengene
单波博士具有超过17年在欧美,中国的新药和仿制药研发和生产经验。目前是德琪医药负责药物早期研发和生产的副总裁。单波博士曾经带领团队完成共计1个国家一类新药的申报上市,多个处于I-III期临床试验的一类新药,以及一系列临床前的项目开发。单波博士带领团队完成了一个国家一类新药生产基地从设计,土建,装修,设备采购到工艺验证和试生产的全过程,包括两条API生产线,一条固体制剂生产线,并且于2018年通过了国家注册现场和GMP动态核查。
单波博士曾先后担任歌礼药业副总裁,凯惠药业(上海)有限公司常务副总经理,上海睿智化学研究有限公司执行总监,GE Healthcare英国研发中心科学家等职务。单博士具有英国Aston大学药物化学博士学位。
Dr. Shan has over 17 years pharmaceutical experience in R&D and manufacturing in Europe and China. Currently, he is the Vice President responsible for Discovery and Early Development at Antengene. In the past years, he lead interdisciplinary teams to deliver a number of IND and NDA programs, delivered one NDA filing and several clinical phase I-III drug candidates. As the site head for one production plant, Dr. Shan was responsible for the construction and validation of the whole production facility which passed the CFDA GMP inspection in 2018.
Prior to his position at Antengene, Dr. Shan held several senior positions for companies, including Ascletis, Chempartner, Gateway Pharmaceutical Ltd and GE Healthcare. Dr. Shan holds a PhD in Chemistry from Aston University in the UK.
Yuanhui Ma
Vice President, Preclinical R&D Department
Haihe Biopharma
Yuanhui Ma, Vice President of Haihe Biopharma, Preclinical R&D Department, Dr. Ma obtained his Ph.D. from Shanghai Jiao Tong University, and went on with organocatalyst research in NTU (Nanyang Technological University) as a postdoctor. He has 10 more years of experience of drug R&D and management, focus on CMC. Dr. Ma joined HaiHe Biopharma in mid of 2016, and set up CMC department. He oversees CMC development and DS/DP manufacturing for all HaiHe’s pipeline products.
Haiqing Yuan
Chief Scientific Officer
Ark Biosciences
Dr. Yuan joined Ark in May 2017 with over 20 years of technical leadership and management experience in drug research and development in the global pharmaceutical industry. He was previously Senior Director of WuXi AppTec, responsible for discovery and medicinal chemistry services and collaborations with biotech, pharma, and institutional customers. Prior to WuXi, Dr. Yuan held various positions of increasing responsibility at Allergan since 2000, where he led drug discovery programs in the areas of GPCRs and nuclear receptors and contributed to the successful pre-clinical development and IND of multiple molecules for applications in metabolic, autoimmune, and inflammatory diseases, and cancer. He was a member of the ocular and dermal delivery review team and participated in the due-diligence for in-licensing and the development of Bimatoprost SR and Juvederm. Dr. Yuan is an inventor of over 40 granted patents and has authored 12 peer reviewed journal articles and book chapters. Dr. Yuan graduated from Fudan University in China and obtained his PhD in Organic Chemistry from Virginia Tech in the US.
Shoufeng Li
Chief Executive Officer
Aucta Pharmaceuticals
Dr. Shoufeng Li is CEO of Aucta Pharmaceuticals, Inc., a research and technology based pharmaceutical company focusing on the development and commercialization of niche generic and branded specialty products. The company's corporate strategy is to focus on proven molecules, and, through innovation, create new therapeutics with lower scientific risk that fulfill unmet medical needs. Its specialty division has a therapeutic focus in CNS, Dermatology, and Other Specialty fields.
Prior to founding Aucta Pharmaceuticals, Dr. Li is Director, Technical Project Leader at Novartis Pharmaceuticals Corporation at East Hanover, NJ, where he managed multidisciplinary project teams, he was responsible for late phase project management and represent CMC function in global project team (GPT). Dr. Li has more than 20 years of multi-national industrial product development experience in both small start-up and multi-national corporations.
Dr. Li's interest and area of expertise is in 505(b)(2) portfolio development and innovation in drug delivery, he has been instrumental in overcoming multiple difficult to formulate bioequivalent products during his tenure at Novartis and was awarded Novartis Leading Scientist Lifetime Award in 2007. He has been invited speakers in international forum on multiple occasions, and has over 30 peer reviewed research articles, reviews and patents. Dr. Li holds Ph.D. in Pharmaceutics and M.S. in Statistics from Rutgers University. He has been actively involved professionally in AAPS, SAPA and BayHelix.
Previous Speaker Bio
Tony (Bizuo) Liu
Chief Executive Officer, Chief Financial Officer
Cellular Biomedicine Group
Mr. Liu formerly served as the Corporate Vice President at Alibaba Group responsible for Alibaba’s overseas investments. Since joining Alibaba in 2009, Tony held various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for the B2C global e-commerce platform. He was also Chief Financial Officer for HiChina, a subsidiary of Alibaba, a leading internet infrastructure service provider.
Prior to joining Alibaba, Tony spent 19 years at Microsoft Corporation where he served in a variety of finance leadership roles. He was the General Manager of Corporate Strategy looking after Microsoft’s China investment strategy and corporate strategic planning process. Tony was a key leader in the Microsoft corporate finance department during the 1990s as the Corporate Accounting Director. He was well recognized within Microsoft for driving an efficient worldwide finance consolidation, reporting, internal management accounting policy process, and showcased Microsoft’s best practices to many Fortune 500 companies in the U.S.
Mr. Liu obtained his Washington State CPA certificate in 1992. He had been serving as an Independent Director and Chairman of the Audit Committee for CBMG since March 2013 and was appointed as Chief Financial Officer in January 2014. He was appointed as Chief Executive Officer of the Company in February 2016.
Xin Lin
Professor and Chairman of the Department of Basic Medical Sciences
School of Medicine
Tsinghua University
Dr. Xin Lin currently is a Professor and the Chairman of the Department of Basic Medical Sciences in Tsinghua University Medical School. Dr. Xin Lin obtained his Ph.D. degree from University of Texas Health Science Center in Houston in 1995. Following a postdoctoral training in UCSF/Gladstone Institutes in San Francisco, Dr. Lin started as an Assistant Professor in the State University of New York at Buffalo in 2000. In 2004 he was recruited to the University of Texas MD Anderson Cancer Center as an Associate Professor. Subsequently, he was promoted to Professor and then Endowed Professor in the University of Texas MD Anderson Cancer Center before his returning to China. He has been studying the molecular mechanism of signal transduction controlling lymphocyte activation, and their impacts on inflammation and anti-microbial and anti-cancer responses. Currently, his lab is developing therapeutic approaches using TCR-T/CAR-T cell methods to target cancer and viral infection.
Alvin Luk
Chief Executive Officer
Neurophth Therapeutics
Dr. Luk is the CEO at Neurophth Therapeutics, Inc. Prior to joining Neurophth, he has served as Senior Vice President and Chief Medical Officer at Shanghai Henlius Biotech, Inc., and he has also held executive roles at various MNCs such as Spark Therapeutics, Inc., Biogen Idec-Hemophilia (acquired by Sanofi), Bayer Schering Pharma LLC., Avigen, Inc.(acquired by Genzyme Corporation) and Tularik, Inc. (acquired by Amgen, Inc.) since 1998. Until 2003, his early researches were primarily investigating gene regulation and expression with the emphasis on rare diseases, oncological diseases, biologics and regenerative medicines. He served on the Clinical Design Committee for rare disease at the U.S. Food and Drug Administration focusing on adaptive clinical trial design to shorten drug development timeline between 2006 and 2009. Under his leadership in strategic drug development, he has won regulatory marketing approvals of 16 products in neurology, ophthalmology, gene/cell therapy, hematology and cancer therapy as of today.
Dr. Luk has published more than 85 book chapters, scientific and medical articles in highly regarded peer-reviewed journals, including New England Journal of Medicine, Nature, Cell, and Science, and is an inventor on over 10 patent applications. Dr. Luk holds an MBA from the Harvard Business School. He is ACRP-certified in clinical research and also received his Ph.D. in Neuroscience from the University of California San Francisco Medical School as well as bachelor’s degree in Molecular and Cell Biology from the University of California Berkeley in the United States.
Su Xiao
Chief Technical Operation Officer
Neurophth Therapeutics
Dr. Su Xiao currently serves as the Chief Technical Operation Officer of Neurophth and she has served as a co-founder and board member of Neurophth since 2019. She has ten years of experience in translational sciences, early and late stage gene therapy development and manufacturing of biologics. Her goal is to make gene therapy affordable and accessible and she has primarily worked for organizations both large and small, including gene therapy development at Pfizer and National Institutes of Health and GMP manufacturing at Vigene Biosciences. She received her B.S. in Chemical Engineering from Tsinghua University and Ph.D. in Chemical and Biomolecular Engineering from the Johns Hopkins University.
Adam Zhao
Chairman
Anlong Bio
Founder of Anlong Biology, Dr. Zhao Chunlin, 1985, the first undergraduate of Department of Biology, Tsinghua University. After graduating in 1990, he went to school in the United States. He received his Ph. D. in molecular biology from the University of Pittsburgh School of Medicine in 1996 and has been doing biological research in the United States for the past eight years. After getting an MBA from Chicago, he moved to business management, where he has more than 30 years of experience in research, multinational enterprises, entrepreneurship and investment. He has rich experience in the field of gene therapy and cooperation with European and American enterprises. Through years of Industry Experience, Dr. Zhao Chunlin believes that gene therapy uses viruses, DNA, its stability and portability is better than protein, gene therapy is a radical cure, and believes that as the technology matures, gene therapy could revolutionize medicine. With the maturity of Gene Biotechnology, Dr. Zhao Chunlin is determined to make his own contribution in the field of biomedicine, especially in gene therapy. At present, the strength of the R & D team is strong, with a large number of excellent doctors and returnees.
Yulong Cheng
Product Manager Asia Cell Therapy
Cytiva
程玉龙 Cytiva 细胞治疗亚太区产品经理
- 中国科学院上海生命科学研究院博士
- 在细胞治疗领域工作多年,负责Cytiva产品的技术支持与推广等工作
- 拥有细胞治疗工业开发和产业化的经验
Ting He
Chief Executive Officer
ImmunoChina Pharmaceuticals
Dr. Ting He is the founder and CEO of Immunochina Pharmaceuticals. Dr. He received his B.S. in biology from Xiamen University and Ph.D. in cancer biology from Tsinghua University. With years of experience in basic research of cancer immunology, he is dedicated to develop innovative CAR-T therapy for treatment of cancer. He was awarded Beijing Nova program and Beijing Eagle Talents.
Brian Min
Chief Executive Officer
GenScript ProBio
Dr. Min graduated from the University of California at Berkeley majoring in Molecular Biology in 1991 and held a Ph.D. in Molecular Biology from the University of California at Los Angeles in 1997. Dr. Min’s expertise includes biologics development from discovery to manufacturing as well as strategic planning and business development.
Dr. Min worked at Amgen in the U.S. as a principal scientist for over 10 years. He was in charge of biologics discovery and optimization, developing multiple protein therapeutics that are currently in clinical trials or on the market. After that, Dr. Min joined Samsung Advanced Institute of Technology. In that job, he worked as the Head of Antibody Engineering responsible for the development of a novel antibody-based therapeutic platform and as a leader for the oncology therapeutic development program. From 2010 to 2011, he carried out the responsibilities as Oncology Program Director in Biosimilar Group and Vice President of Strategic Business Development Group, focusing on antibody biosimilars development. From 2012 to 2017, he worked as Vice President of Process Team at Samsung Bioepis Co., Ltd. With responsibilities covering a full range of upstream and downstream process development, as well as tech transfer and GMP production. Just before joining GenScript, in 2018, Dr. Min worked at the Drug Substance Team of Samsung Bioepis Co, Ltd. as a senior Vice President, leading the process development of all biosimilars and new biologics in Samsung’s pipeline.
Xinpo Jiang
Senior Director of Analytical, Process Validation, QC, QA
Legend Biotech
Dr. Xinpo Jiang, Senior Director of Analytical Department/QA/QC at Legend Biotech, works on development of novel CAR T products in the pipeline. He was CMC Head leading LCAR-B38M CAR T product to clinical trial in China and US (collaborating with Janssen). He was Director of Pharmacology Department at GenScript for assay developments on biologicals and developed many cell-based and biochemical assays, oncology and antibody related functional assays. He received his Doctor of Philosophy from University of Minnesota, Twin Cities. He did a postdoctoral fellowship at Toronto Western Hospital, University of Toronto. Prior to his position at GenScript, Dr. Jiang was a research scientist at NeuroMed Pharmaceuticals. He published around 20 peer-reviewed journal articles and filed around ten patents.
Yi Li
President and Chief Scientific Officer
Guangdong Xiangxue Life Sciences
Yi Li, Ph.D. University of Leicester, UK, the National Distinguished Expert, Leading Talent of Guangdong Province, President and CSO of Guangdong Xiangxue Life Sciences, LTD, Principal Investigator of Center for Infection & Immunity at Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, PI at the State Key Laboratory of Respiratory Diseases. He has been engaged in the development of antibody and T cell receptor drugs in the UK for a long time. Representative papers have been published in Nature Biotechnology, Nature Medicine, JBC, Molecular Cancer Therapy, etc. He pioneered the application of phage display technology to the directed evolution of T cell receptors. He developed the world first human high-affinity soluble TCR, which the affinity for recognizing pHLA was increased by more than one million times as a key breakthrough in the field of TCR. Under his leadership his team has successfully developed a number of high-affinity TCRs at Immunocore in the UK, which has eventually been used in FDA-approved immunotherapy clinical research products. In 2012, he returned to China and led the establishment of China's first high-affinity TCR-mediated T cell therapy platform. The TCR-T product TAEST16001 injection developed by the Xiangxue team has obtained the first TCR-T IND approved by CDE of the National Medical Products Administration.
Enxiu Wang
Founder and Chief Executive Officer
Nanjing CART Medical Technology
CAR-T therapy specialist, technical core personel in Carl June group at UPENN. Dr. Wang has long engaged in CAR design-evaluation, he is the participant in the first CAR-T drug R&D. He takes the lead in solid tumor CAR design and achieved recognition. He accomplished two solid tumor CAR-T patents together with Dr. Carl June and Dr. Michael Milone.
After returning to China, he finished the early exploration of donor CAR-T infusion for ALL patient and got succuess. Now Dr. Wang's team has been authorized two patents for invention. 25 patents application has been accepted by SIPO(State Intellectual Property Office). Multiple IIT clinical trials with Dr. Wang's CAR-T products have been carried out both in hematologic malignancies and solid tumors treatment.
Hermann Bohnenkamp
VP Business Development APAC
Miltenyi Biotec
As Vice President of Business Development APAC at Miltenyi Biotec, Hermann is responsible for Miltenyi’s strategic collaborations with Biotech and Pharma in Cell and Gene Therapy (CGT) in Asia. Joining Miltenyi Biotec in 2009, he was instrumental in building Miltenyi’s cell and gene therapy business as Business Area Manager, including the release of key ancillary materials and the T Cell Transduction Prodigy platform. In 2016 he led Miltenyi’s Australian business as Managing Director. Before joining Miltenyi, Hermann was responsible for the project management for early drug and monoclonal antibody development at MediGene Immunotherapies, Munich. He holds a doctoral degree from the University of Bonn and the Helmholtz Research Center Juelich for studies on bioprocess development of DCs and ACT in solid tumor indications. He continued similar studies at King’s College London (Guy’s Hospital) with Cancer Research UK.
Silvio Weber
Head of the Industrial Process Development Team
Miltenyi Biotec
As the Head of the Industrial Process Development Team at Miltenyi Biotec, Silvio is responsible to provide automated Cell and Gene Therapy procedures on the CliniMACS Prodigy for industrial customers. Silvio has more than 10 years of R&D experience in various fields of cell biology, including Immunology, Regenerative Medicine and Pharmacology. After joining Miltenyi, Silvio has been coordinating custom-tailored development of automated processes for T-cell mediated Immunotherapy, Stem Cell Engineering and other innovative Cell and Gene Therapy approaches using the Miltenyi Biotec CliniMACS Prodigy platform. Silvio holds a Diploma degree in Biochemistry from the University of Bielefeld and a Doctoral degree in Biochemistry from the University of Kiel.
Sun Yan
Vice President, General Manager, Cell Drug Business Unit
Shanghai Cell Therapy Group
孙艳,上海细胞治疗集团副总裁,细胞药物BU总经理,主要从事CAR-T细胞药物开发及相关管理工作。带领团队完成国内首个非病毒载体CAR-T细胞药物的研究及注册申报,获得临床试验许可。
Pete Gagnon
CSO
BIA Separations
Pete Gagnon is a widely respected global authority in the field of downstream processing. He is the author or more than 100 scientific publications and inventor on more than 100 awarded patents in the United States, Europe, and Asia. His expertise covers purification of monoclonal antibodies, virus particles, extra-cellular vesicles, plasmid DNA, and mRNA. He is currently Chief Scientific Officer at BIA Separations, a European manufacturer of specialized chromatography media for purification of gene therapy products.
Wen Wang
Chief Medical Officer
IASO Biotherapeutics
Dr. Wen (Maxwell) Wang currently is the Chief Medical Officer in IASO Biotherapeutics Co., Ltd. He obtained his M.D. degree in Wuerzburg University in Germany and Ph.D. degree from University of Aberdeen in UK and then did his postdoctoral training in at UConn Health Center in USA.
Dr. Wang has over 7 years of experience in Chinese Leading cell therapy companies including JW Therapeutics, Cellular Biomedicine Group (Nasdaq: CBMG) in clinical, preclinical, and translational development including CART cell and stem cell therapy. He held one of leading position in the 1st Chinese CD19-targeted CART cell and Mesenchymal Stem Cell INDs.
Before industry career, Dr. Wang worked as a Resident and Attending in Orthopedic Department in Shanghai TCM Hospital for 5 years.
Mingjun Wang
Executive President
Shenzhen Institute for Innovation and Translational Medicine
Dr. Mingjun Wang,Executive President of Shenzhen Institute for Innovation and Translational Medicine, received his MD from Anhui Medical University in China and his PhD degree in Cellular Immunology from the University of Copenhagen in Denmark in 2009, and finished his postdoctoral training in cancer immunology at Baylor College of Medicine in Houston of the United States. His research is focused on identification of cancer antigens and the development of T cell-based cancer immunotherapy using TIL, TCR-T cells or CAR-T cells for various types of malignancies. Dr. Mingjun Wang has published more than 30 peer-reviewed papers and three book chapters in the field of cancer immunology.
Xiaoliang Sang
Regional Commercial GM-Asia Cell & Cene Therapy
Cytiva
Summary
• XIAOLIANG works with senior leadership teams of Cytiva in Asia Cell & Gene Therapy markets to develop profitable go-to-market growth strategies. With over 15 years successful commercial experiences in Pharmaceutical industry, XIAOLIANHG helps clients assess dynamics of their needs and grow their business further more.
• XIAOLIANG has worked in life science industry (IVD, Academia, Bio-Pharma, Cell & Gene Therapy) for around 20 years and brings a wealth of experience to every client engagement. His deep knowledge, networking and experience of Industry-Academia-Research platform has accelerated many small-/medium-size firms to scale up and go-to-market in past 10 years.
XIAOLIANG earned his Mini MBA and Diploma Leadership Development Program from China Europe International Business School, with honors, and his Bachelor of Science degree from ZheJiang University.
Yu Zhang
SVP & CSO
VCANBIO Cell & Gene Engineering
Dr. Zhang Yu is the president and CEO of Aeon Therapeutics Inc., a joint-venture biotech company established by Eureka Therapeutics Inc. and Vcanbio Cell&Gene Engineering Co.,Ltd. Prior to found Aeon, Dr. Zhang acted as assistant president and senior strategic planning expert in Vcanbio. Dr. Zhang received his B.S. in Bioengineering and M.S. in Biomedical Engineering from Beihang University, and Ph.D. in Stem Cell and Regenerative Medicine from Heinrich-Heine-Universität Düsseldorf in Germany. Before the industrial career, he worked in Rhine Forum, University of Applied Sciences Bonn-Rhein-Sieg, and was a visiting scholar in German Aerospace Center and University of Palermo. He is a member of German Society of Stem Cell, Chinese Society of Cell Biology, and reviewer of several journals, e.g. Current Stem Cell Research&Therapy. Dr. Zhang was the winner of “131 talent plan”and “Tianjin Green Card Plan”.
Biao Zheng
Chief Scientific Officer
IASO Biotherapeutics
Dr. Biao Zheng graduated with a medical degree from Zhejiang University School of Medicine. He received his PhD in Immunology from King’s College, University of London. Dr. Zheng served at the faculty of University of Maryland School of Medicine and Duke University Medical Center 1996-1999. He has been a professor in the Department of Pathology and Immunology, Baylor College of Medicine since 1999. Dr. Zheng joined GlaxoSmithKline R&D Center in 2010 as the head of Immunological Discovery Sciences. He was the vice president of Global Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific, from 2015 to 2018, responsible for the innovative immunological drug pipeline in the region. He was the Chief Scientific Officer of Genfleet Therapeutics 2018-2020. Dr. Zheng recently joined Iaso Biotherapeutics as the Chief Scientific Officer.
Dr. Zheng is an experienced physician scientist, drug hunter, and professor with a demonstrated history working both in academia and pharmaceutical industry. He has more than thirty years of experience in biomedical research and drug discovery. He has published extensively in world top journals including Nature and Science. His major areas of research and development include autoimmune diseases, immuno-oncology, and novel vaccine development.
Tony Zhang
Chairman & CEO
Wuhan Bio-Raid Biotech
Tong-Cun, Zhang, Ph.D, M.D; a distinguished professor in Hubei Province, is currently the Dean of College of Life Sciences and Health at Wuhan University of Science and Technology(WUST).
Dr. Zhang has got his Ph.D degree in 2000 from Institute of Biophysics, Chinese Academy of Sciences. Dr. Zhang was once honored with the of NRC Postdoctoral Fellowship Award in 2000-2003 in USA and then joined in UNC at Chapel Hill as assistant professor. Since 2012 he has taken a full-time professor and dean in WUST.
Dr. Zhang has aimed to the scientific research of the gene regulation, related to human diseases and development of biological drugs. In recent years, he has focus on CAR-T cell therapy for blood and solid cancers. His team has carried out novel CAR-T clinical trial in several hospitals and got excellent clinical effects and safety, which were published in Blood and Leukemia. CAR-T targeting to CD30 is trialed in clinical phase I.
Dr. Zhang has obtained several grants from The National Natural Science Foundation of China and ministry of Science and Technology, including National Key Research Program, 863 Programs, 973 Program. He has published over 100 theses in relevant research fields at high level scientific Journals. Novel patents for CAR-T cell-therapy over world has been obtained in his leading team.
Since he come back China, Dr. Zhang has been honored with local and national talent and outstanding titles. He was also awarded US-EPA's Scientific and Technological Achievement Award in 2003.
James Chen
CEO
INNOVEL
陈皓先生
英诺维尔智能科技(苏州)有限公司
创始人,CEO/总工程师
*GE 智能控制系统高级研发经理
*AMAI半导体设备系统工程师
*10年+ 复杂系统研发与管理经验
*英国巴斯大学控制工程硕士研究生
*北京航空航天大学飞行器设计
*北京航空航天大学通讯工程
重要项目经验
*3000米+ 超深水钻井系统控制系统
*深水转井多组态液相防喷预测系统
*C19 IMA架构通讯导航系统
*ARJ21机载核心控制网络
*10代TFT-LCD液晶面板CVD系统
*300mm晶圆45nm PVD系统
均有10年以上大型项目经验,丰富的一线实战经验,强大的执行力
Liming Yang
Chairman & CEO
Wyze Biotech Co., Ltd
Dr. Liming Yang is the Co-founder and Chairman at Wyze Biotech Co., Ltd, a Hangzhou China based clinic stage company, engaged in the development and commercialization of novel allogeneic DNT (Double Negative T) cells and off-the-shelf cell immunotherapies to improve the lives of cancer patients and their overall survival by leveraging the clinically validated DNT cell technology. The first-in-class phase I clinic trial to relapsed AML patients after allo-HSCT has been finished in June 2020 with very promising clinic data. The IND application of RC1012 injection to r/r AML has recently been accepted by CDE of NMPA. Dr. Yang was associate director of product development in Stemgent and quality control manager in BD Biosciences Pharmingen, both based in San Diego, California, USA. He also worked previously as postdoctoral fellow at University of Toronto, Canada on DNT project and is one of the key inventors of DNT technology. Dr. Yang served as PI and associate professor when he worked in Medical School at Shanghai Jiaotong University in China. He received his M.D. from the Medical School at the Zhejiang University and finished his joint Ph.D. program in both Shanghai Jiaotong University in China and University of Toronto in Canada. Dr. Yang has published nearly 30 papers in peer-reviewed journals including first author in Nature Medicine and is an inventor on 5 patent applications in the field of DNT Technology.s
Wei Wang
Vice President, Clinical Development
CARsgen Therapeutics
Dr. Wei Wang is the Vice President of Clinical Development at CARsgen. She leads CAR-T and monoclonal antibodies China clinical development programs and manages medical affairs, clinical operation, biometrics and pharmacovigilance.
She has over a decade experiences in China and global clinical development programs in Merck, Novartis and Pfizer, managing team in clinical development, medical affairs and pharmacovigilance. Dr. Wei Wang worked as the practicing pediatric physician for 6 years in Xiangya Hospital of Central South University. She earned her Master degree in clinical medicine from Central South University, and the M.D. & Ph.D. degree from Fudan University.
Xinxin Wang
Group leader for TruUCAR™ platform development
Gracell Biotechnologies
Dr. Wang received her PhD in Immunology from Washington University in St. Louis, focusing on T cell signaling transduction and T cell engineering. During her Postdoc research in Scripps-Calibr and her work as senior scientist at Poseida Therapeutics, Dr. Wang participated and led the development of multiple autologous and allogeneic CAR-T programs using different platform technologies. She joint Gracell Biotechnologies in 2018 and had led the development of “off-the-shelf” CAR-T program since then.
Lyu Lulu
Chief Executive Officer
Juventas Cell Therapy
Dr. Lyu Lulu obtained her Ph.D. in clinical medicine (internal medicine, hematology) in 2006. Prior to 2007, she mainly undertook the clinical and scientific research on hematopoietic and mesenchymal stem cells. In 2001, Dr. Lyu participated in the first umbilical cord blood transplantation in China for the treatment of childhood leukemia. She pioneered and established the domestic technology of isolating mesenchymal stem cells from the umbilical cord in 2004. In the following year, she continued her research on hematopoietic cell transplantation and mesenchymal stem cells at Westchester Medical Center of New York Medical College. Dr. Lyu published various papers in domestic and international journals. After joining a multinational pharmaceutical company in 2007, Dr. Lyu was engaged in the research and development of innovative drugs and the strategic planning for new products in the fields of hematology and oncology for more than a decade. With key appointments being held in multinational companies including Novartis, Genzyme, Roche, AstraZeneca, and Merck, she has garnered a wealth of experience in R&D and product life-cycle management in the areas of targeted drugs, immunotherapy, and cell therapy. In addition, she has played a vital role in the R&D, registration, and market expansion of ground-breaking products for treating cancers such as Gleevec®, Herceptin®, Tagrisso®, and Keytruda®. In June 2018, Dr. Lyu left the international pharmaceutical corporate world to become a trailblazer focusing on the development of innovative drugs domestically. As the current CEO of Juventas Cell Therapy Ltd., she is committed to promoting the clinical research of cell therapy and to pushing forward the industrialization thereof, thus creating world-leading products based on cell therapy.
Cheng Liu
Founder and CEO
Eureka Therapeutics
Dr. Cheng Liu is the founder and CEO of Eureka Therapeutics. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a PhD in Molecular Cell Biology from the University of California, Berkeley.
Henry Ji
President and Chief Executive Officer
Sorrento Therapeutics
Henry Ji, Ph.D., co-founded and has served as a director of Sorrento since January 2006, and as its Chief Executive Officer and President since September 2012. Dr. Ji served as Sorrento’s Chief Scientific Officer from November 2008 to September 2012 and as its Interim Chief Executive Officer from April 2011 to September 2012.
Dr. Ji served as VP of Sales and Business Development at CombiMatrix, and was responsible for strategic technology alliances. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as VP of Business Development at Stratagene (later acquired by Agilent Technologies), a biotechnology company. In 1997, Dr. Ji co-founded Stratagene Genomics, a wholly-owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer and Director from its founding until 1999. Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. He held many executive positions in biotechnology and life sciences companies during his career.
Jianqiang Li
Founder & Chief Scientific Officer
Hebei Senlang Biotech
Jianqiang Li is currently the Founder and Chief Science Officer of Hebei Senlang Biotech, a company focuses on the development and clinical translation of next generation cell therapy technology. Dr. Li obtained his PhD degree from University of Wuerzburg in Germany. He did his postdoctoral training at City of Hope and Fred Hutchinson CRC. His expertise covered the following fields: Gene modified adoptive T cell therapy; In vitro expansion and gene editing of Hematopoietic stem cells; Transplant Immunology.
Lin Yang
Founder and Chairman
PersonGen BioTherapeutics
Dr. Lin Yang is currently a Distinguished Professor at the Cyrus Tang Hematology Center of Soochow University, China, and an adjunct professor of Department of Lymphoma and Myeloma at the MD Anderson Cancer Center, USA. Dr. Yang is the founder/chairman/chief scientific officer of PersonGen BioTherapeutics (Suzhou) Co., Ltd., and Chairman/CEO of PersonGen-Anke Cellular Therapeutics Co., Ltd. Dr. Yang received many awards, including Innovation and Entrepreneurship Talent of Jiangsu Province, Six Peak Talent of Jiangsu Province, Gusu Innovation and Entrepreneur Leading Talent, Pioneer of Suzhou Industrial Park Technology, Nanjing “321” Technology Leaders, Second Prize of China Innovation and Entrepreneurship Competition, and many other honorary titles and awards. He has published more than 70 research articles in recognized peer reviewed journals, such as Cancer Cell, Cancer Research, Oncogene, JBC, and Cancer Science, etc., which were all funded by international, national and provincial foundations.
As a principle investigator, Dr. Yang plays a major role in the immunotherapy of CAR-T cells and CAR-NK cells of China, and has obtained impressive achievements in the industrialization and clinical trials of CAR-T cell therapy. Among them, several clinical trials are the first-in human projects performed globally, including CAR-T cell therapy for T-cell acute lymphoblastic leukemia, and 4th generation CAR-T cell therapy for solid tumors. Led by Dr. Yang, PersonGen-Anke’s CD19-CAR-T product has been submitted to Chinese FDA and is being under the evaluation process which is expected an approval from CFDA within next few months.
Jishuai Zhang
Chief Scientific Officer
The Pregene Biopharma Company
As the Chief Scientific Officer in Shenzhen PREGENE Biopharma Company, Ltd, Dr. Zhang Jishuai graduated from Zhengzhou University, receiving a B.S. degree in clinical medicine. Then, he got his M.S. degree in molecular immunology in the Fourth Military Medical University, and Ph.D. in genetics in Beijing Institute of Biotechnology. After that, he obtained the postdoctoral training in the Hormel Institute in the University of Minnesota.
As an expert on tumor biology, Dr. Zhang once did detailed study on tumor gene function (including tumor initiation, differentiation and metastasis), about which he published over 20 papers. In 2016, he founded the PREGENE Company and acted as the Chief Scientific Officer, from which he began the research and development of CART drug. Having built a platform of “Nanobody discovery, CART research and drug development”, PREGENE is now mainly focused on CART therapy for hematologic tumors.
Yi Zhu
China Business Head
T-Cure Bioscience
Dr. Zhu has over 10 years’ experience in drug development, clinical operation, financial investment and business development in healthcare area, especially in the field of cell therapies. He got his Ph.D in Immunology from Duke University Medical Center and B.S. in Genetics from Fudan University. Initially he committed himself as a scientist by serving the GSK China R&D Center to identify new drug targets for neuro-inflammation diseases. This helped him to further develop his career as a Principal Investigator in Xinhua Hospital in Shanghai working on the MIF soluble receptor. He joined Novartis as the new translational medicine department was founded and became the Clinical Trial Leader for Asia Pacific region. At that time, he led several global multi-center studies including one Gleevec Ph III Trial. Dr. Zhu started to explore his new career track in financial investment after he was awarded his MBA degree from Fudan University. He focused on new technology innovation and rising stars in the cell therapy area. Prior to joining T-Cure Bioscience, Dr. Zhu was the BD head of Hrain Biotech and in charge of the licensing and financing of this well-known CART company in China.
Hui Wang
Deputy Director, Clinical Diagnostic Dept.
Director, Flow Cytometry Lab
Lu Daopei Medical Group
Hui Wang, MD, is the Deputy Director of the Clinical Diagnostic Department(vice chairman grade), and Director of Flow Cytometry Lab at the Ludaopei Medical Group, as well as Director, CEO, and CMO of Synarc Research Laboratory (Beijing) Ltd.
Dr. Wang graduated from the Peking University Health Science Center.
She completed internal medical residency at the Beijing Shijitan Hospital, followed by a fellowship in Hematology Institute at the People’s hospital. She then joined the faculty at Ludaopei Medical Group in 2008. She primary area of clinical research is the clinical diagnosis of flow cytometry. Having been worked in flow cytometry field for 18 years, She has signed more than 300,000 diagnostic reports of immunophenotyping and MRD detection, of which more than 40% coming from other hospitals around China.
She has taken part in writing 10 professional books, given nearly 600 professional oral presentations in 29 provinces of China(including Taiwan). She has hundreds of students from over 100 well-known hospitals, distributed in 26 provinces of China (including Taiwan).
The chairman of flow cytometry branch of professional committee on laboratory medicine, Chinese association of integrated traditional and western medicine
The vice chairman of blood & body fluid branch of Beijing Medical Laboratory Society
The standing committee member of hematology branch of Chinese non-public Medical Association
The standing committee member of Chinese flow cytometry Union
The member and special expert of lymphoma branch of Chinese Anti-cancer Association, flow cytometry branch of Chinese society of hematology and immunology, cell analysis special committee of Chinese society of bioengineering, and other societies.
Dayu Hu
Chief Operating Officer
Asclepius Technology Company Group
胡大裕,华中科技大学同济医学院药理学博士,拥有20多年的药品研发和医药行业管理经验,曾担任湖北省中医药大学附属医院药学部副主任、康诚科瑞医药研发(武汉)有限公司总经理。现任阿思科力(苏州)生物科技有限公司首席运营官。负责公司CAR-NK肿瘤免疫细胞药物产业化发展。 阿思科力专注于研发肿瘤免疫治疗货架细胞药物,其第一代广谱CAR-NK细胞药物治疗晚期癌症达到76.5%疾病控制率,在国际上处于领先地位。
Jijun Yuan
Chief Executive Officer
Shanghai Genbase Biotechnology
Dr. Jijun Yuan is co-founder and chief executive officer of Shanghai Genbase Biotechnology Co. Ltd, which was established in 2015 to focus on developing new therapeutic drugs, including cell therapies, gene therapies and therapeutic antibodies. Prior to that, Dr. Jijun Yuan spent six years at Shanghai Hengrui Pharmaceutical Co. as the associate director in charge of the biological division. He has been involved in more than 30 drug discovery programs, including oncology, diabetes and cardiovascular therapeutic drugs. Dr. Jijun Yuan holds a PhD degree in molecular biology from Ohio State University and worked as postdoctoral researcher at University of California Los Angeles.
Stephan Grupp
Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, Medical Director of The Cell and Gene Therapy Lab
Children’s Hospital of Philadelphia (CHOP)
Stephan Grupp, MD PhD, is the Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, and Medical Director of The Cell and Gene Therapy Lab at the Children’s Hospital of Philadelphia (CHOP), as well as the Yetta Dietch Novotny Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine.
Dr. Grupp graduated from the University of Cincinnati after completing the MD/PhD program with a PhD in Immunology.
He completed pediatric residency at the Boston Children’s Hospital, followed by a fellowship in Pediatric Hematology/Oncology at the Dana Farber Cancer Institute and postdoctoral work in Immunology at Harvard University. He then joined the faculty at Harvard University until 1996, when he came to CHOP. His primary area of clinical research is the use of CAR T and other engineered cell therapies in relapsed pediatric cancers. He led all of the pediatric ALL trials of CTL019 (now approved as Kymriah), including the largest and most successful engineered T cell therapy clinical trial conducted to date (1, 2), as well as the global registration trial for CTL019 (3). As a result of this work, he presented the Clinical Perspective at the July 2018 FDA ODAC meeting, at which reviewers voted 10-0 for recommendation of approval for Kymriah in pediatric ALL. His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers. Dr. Grupp is a reviewer for several journals and the author of over 200 peer-reviewed journal articles, as well as numerous abstracts and book chapters.
Yangbing Zhao
Director, T Cell Engineering Laboratory, Center for Cellular Immunotherapies
University of Pennsylvania School of Medicine
Scientific Co-founder
Tmunity Therapeutics
Dr. Yangbing Zhao is an Associate Professor and the Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the University of Pennsylvania. He received an MD and PhD in Immunology from the Third Medical University in Chongqing, China. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells allogeneic bone marrow transplantation. For the next two years he was a research associate at Duke University Medical Center, where he worked on RNA transfected dendritic cell vaccines against cancers. In 2003, he joined Dr. Steven Rosenberg’s group as a senior research fellow at the Surgery Branch of the National Cancer Institute, where his research work directly led to clinical trials of treating cancer patients with T cells against Mart1, NY-ESO-1, Her2/Neu, CD19 (Yescarta) and VEGFR. He joined the faculty of the Department of Pathology and Laboratory Medicine, University of Pennsylvania in 2009 as the Director of TCEL. his research work at the University of Pennsylvania led to clinical trials to treat cancer patients with TCRT or CART against NY-ESO-1, CD19 (kymriah), Mesothelin, cMet, GD2 and CD123, as well as first in human CRISPR/CAS9 application in the world. Dr. Zhao has more than 20 years’ experiences in T cell engineering with over 50 publications and filed over 90 patents in the CART field. Dr. Zhao is the scientific co-founder of Tmunity Therapeutics.
Xiuyan Wang
Assistant Director, Michael G.Harris Cell Therapy and Cell Engineering Facility
Associate Laboratory Member, Department of Molecular Pharmacology
Memorial Sloan Kettering Cancer Center
Dr. Wang was trained by Dr. Adolfo García-Sastre and received her Ph.D. in Biomedical Sciences from the Mount Sinai School of Medicine in NYC. She joined Dr. Peter Cresswell’s laboratory in the Department of Immunology at Yale University as a Howard Hughes Medical Institute fellow, and later as a Cancer Research Institute postdoctoral associate. Dr. Wang joined Memorial Sloan Kettering Cancer Center in 2007, and is currently an Associate Lab Member in Department of Molecular Pharmacology, and the Assistant Director of the Michael G Harris Cell Therapy and Cell Engineering Facility. Dr. Wang is in charge of the R&D, process development and manufacturing. She has overseen the successful manufacturing of all the CAR T cell products used in 13 phase I/II clinical trials as well as over 20 batches of cGMP grade viral vectors. She served in the translational science and product development committee in the American Society of Gene and Cell Therapy (ASGCT). She is currently a member for the National Heart, Lung and Blood Institute (NHLBI) independent external panel and a committee member for the Alliance of Regenerate Medicine (ARM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).
Yajin (Jenny) Ni
Senior Director, Process & Product Development, Technical Operations
Allogene Therapeutics
Dr. Ni is Senior Director, Process & Product Development at Allogene Therapeutics, leading the company’s manufacturing process development activities for its pipeline of off-the-shelf CART candidates. During her tenure at Allogeneic Therapeutics and previously at Pfizer from 2015 to now, she has led her team to establish platform allogeneic CART manufacturing processes for enabling pipeline programs quickly advancing to early clinical testing using robust enough 1st generation process and transiting to late stage clinical & commercial manufacturing using more controlled 2nd generation automated & closed process. From 2000 to 2010 she held a senior technical role at VIRxSYS, where she conducted pioneering adaptive T cell therapy development work using lentiviral vector modified autologous CD4 T cells for HIV infection together with Dr. Carl June’s lab at the University of Pennsylvania. Through that work, they were 1st to bring lentiviral vector modified autologous adoptive T cell therapy into the clinic, and 1st to demonstrate feasibility of large scale GMP manufacturing of lentiviral vector and ex vivo expansion of gene-modified T cells in WAVE bioreactor. That work also accumulated a large set of patient safety data for lentiviral vector modified adaptive T cell therapy and laid down the groundwork for lentivector modified autologous CART therapy to be first tested in the clinic by Dr. Carl June’s lab. Dr. Ni earned a M.D. in internal medicine from the Kunming Medical College, P.R. China and received her Ph.D. in virology from the Kyoto University, Japan. She then conducted post-doctoral training in gene delivery at the NIH, USA before embarking on her gene & cell therapy product development career in both small biotech and big pharma.
吴宇轩
研发副总裁
上海邦耀生物科技有限公司
吴宇轩,上海邦耀生物科技有限公司研发副总裁,华东师范大学生命科学学院研究员,博士生导师,入选上海市浦江人才计划,东方学者岗位计划。2015-2018年,在哈佛医学院和波士顿儿童医院进行博士后研究期间,开发和优化了造血干细胞中基于CRISPR/Cas9的基因编辑系统,通过高效激活胎儿血红蛋白的表达来治疗地中海贫血及镰刀状贫血疾病,相关疗法被美国FDA批准进入临床实验阶段,初步临床结果显示出了极佳的治疗效果。同时在国内与各大医院合作推动地中海贫血的基因治疗。以第一作者或共同通讯作者在Nature Medicine(2 篇)、Cell Stem Cell(2 篇)和Cell Research(1 篇)等国际著名期刊上发表研究论文多篇。
刘滨磊
董事长
武汉滨会生物科技股份有限公司
刘滨磊教授,武汉滨会生物科技股份有限公司董事长,博士生导师,湖北工业大学特聘教授,湖北省百人计划入选者,曾任中国抗癌协会生物治疗专业委员会常委和中国免疫学会肿瘤免疫与生物治疗分会常委。
刘滨磊博士长期致力于肿瘤免疫及溶瘤病毒研究,其在英国BioVex生物技术公司原研的溶瘤病毒注射液(T-VEC)已被美国FDA及欧盟EMEA批准上市销售。归国后,刘滨磊教授带领国内研究团队研发出具有溶瘤活性更高及增强抗肿瘤免疫特点的新型溶瘤病毒OH2,其专利已授权。OH2溶瘤病毒已获NMPA临床试验批文并完成两项临床I期研究(黑色素瘤和其它实体瘤)。已获得的立项资助有十三五重大新药创制、973、863、十二五支撑项目、自然科学基金等。迄今为止,已在国内外杂志发表近40余篇科研论文。
Previous Speaker Bio
Kerry L. Blanchard
Chief Executive Officer
Everest Medicines
Dr. Blanchard’s career spans four decades in diverse leadership roles across North America and Asia. In February 2020 he was appointed as CEO of Everest Medicines after having served as Operating Partner at CBC Group, a healthcare private equity firm and one of the leading investors in Everest Medicines, since November 2019. Prior to CBC Group, he was Chief Science Officer at Innovent Biologics, where he oversaw the NDA preparation and submission for the company’s PD1 antibody, sintilimab, which was approved in late 2018 and launched in China in 2019 and led the partnership efforts with Incyte to develop three small molecule oncology assets for Greater China. Previously, Dr. Blanchard was the Senior Vice President of Lilly China Drug Development and External Innovation, where he built and led the development and medical affairs teams, who designed and implemented clinical plans for assets across all therapeutic areas. He also built and executed the company’s external partnership drug development portfolio model in China. He positioned Lilly to capitalize on the positive changes in the Chinese regulatory environment to expand the China innovation ecosystem. He built multiple successful partnerships that delivered new medicines to the China market including Innovent Biologics (sintilimab) and Chi-Med (fruquintinib). At Eli Lilly and Company he also initiated the project and led the team who delivered abemaciclib, the best in class cdk4/6 inhibitor, to the clinic.
His interests include discovering and developing medicines and the application of translational research principles to drug discovery. He was a co-founder and a member of the Board of Directors of the Asian Cancer Research Group, a not-for-profit company focused on the generation and dissemination of genetic and clinical data on cancers of importance in Asia. Dr. Blanchard received a BS degree in chemistry in 1977, a PhD in Biochemistry in 1982, and an MD in 1985 from Indiana University. He completed a residency in Internal Medicine and fellowships in Hematology and Medical Oncology at the Brigham and Women’s Hospital, the Dana Farber Cancer Institute, and Harvard Medical School in 1990. Dr. Blanchard was a Damon Runyon Fellow and a Fellow of the American Cancer Society. Prior to coming to Eli Lilly and Company in 2000, he was a tenured Professor of Medicine and Biochemistry & Molecular Biology at Louisiana State University Health Sciences Center in Shreveport, LA. He has had multiple global roles in Lilly Research Laboratories including Senior Clinical Research Physician in Program Phase Oncology, Chief Scientific Officer Cancer Discovery, Executive Director of Cancer Discovery & Lilly Systems Biology-Singapore, Chief Operating Officer/Vice-President of Discovery Research and Vice-President of Integrative Biology, and Vice-President of Tailored Therapeutics. He was a member of the board for Lilly China and Zymeworks INC and is a member of the board for The Confucius Institute in Indianapolis; he is also a member of the scientific advisory board for CBmed GmbH in Graz, Austria.
Blake Salisbury
Vice President of Business Development
Innovent Bio
Mr. Blake Salisbury is responsible for BD activities at Innovent, where he has lead the partnering efforts for cross border deals with Lilly, Roche, Coherus, Alector, Hanmi, MD Anderson, and others. He received his MBA from Thunderbird Graduate School of Global Management. He has 29 years of experience in pharma/biotech, primarily in business development (22 years), but also in sales, marketing, and pricing. Prior to joining Innovent, Blake spent almost 24 years with Eli Lilly and Company where he closed over 50 transactions of various types.
Xian-Ping Lu
Chairman & CEO
Chipscreen Biosciences
Dr. Xian-Ping Lu founded Shenzhen Chipscreen Biosciences, the leading drug discovery and development company in China focusing on innovative small molecular therapeutics, 19 years ago with a group of US-trained professionals. Previously he was Director of Research at Galderma R&D in Princeton until 2000, the year he became visiting professor at China’s State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University. He also participated in founding Galderma Research Inc. and Maxia Pharmaceuticals in San Diego around 1994.
Dr. Lu came to the US in 1989 for postgraduate fellowship study at the Department of Pharmacology, University of California in San Diego, followed by research at La Jolla Cancer Research Foundation (Burnham Institute). He obtained his Ph.D. in Molecular Biology and M.S. in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his B.S. degree in Biochemistry from Sichuan University.
With over 30 years of biomedical research and biotech/pharmaceutical experiences in various therapeutic areas, Dr. Lu is a skilled leader of diverse groups in global operating settings. He has published more than 100 peer-reviewed papers in prestigious journals including Nature, Science and The Lancet Oncology. He is the lead inventor of over 100 patented inventions in areas of small molecule therapeutics.
Jun Bao
President & CEO
IMPACT Therapeutics
包骏博士,英派药业总裁、首席执行官。包骏博士在药物研发、技术转让、 许可和业务拓展、风险投资、创业和公司融资方面拥有超过二十年的丰富经 验。曾任珅奥基医药公司资深副总裁兼首席商务官、跨国药企葛兰素史克全 球业务发展总监兼中国区主管,美国著名癌症医药公司Onyx企业发展和融资 规划总监,之前曾就职于ICOS公司、Cell Therapeutics公司负责肿瘤学领域 内的技术许可和业务发展。包博士拥有美国堪萨斯大学博士学位、约翰霍普 金斯博士后及芝加哥大学MBA学位。曾担任百华协会董事。
Cunxiang Ju
R&D Director
GemPharmatech
琚存祥博士 江苏集萃药康生物科技有限公司研发总监
微生物与免疫学博士;曾担任南京大学-南京生物医药研究院副院长、研发总监,拥有丰富的大小鼠品系研发项目经验,全面负责基因组编辑新技术平台的开发及人源化实验动物的创制。带领团队将CRISPR/Cas9技术用于同源重组的效率提高了10倍以上,成功开发了BALB/c、NOD等不同遗传背景来源的胚胎干细胞株,并成功开发了一系列用于抗体药物筛选的人源化动物模型,包括hPD1、hPDL1、hOX40、hCD3e、hCTLA4、hCD137、hTIGIT等单靶点及对应双靶点的模型,这些模型已经实现了市场转化,获得了良好的经济效益。
Patrick Lu
President & CEO
Sirnaomics
陆阳(Patrick Lu)博士是美国Sirnaomics, Inc.(圣诺制药) 创始人、董事长和CEO,苏州圣诺和广州纳泰两家分公司的董事长,国家特聘专家。陆博士自1993年以来,在诺华药业(Novartis)和代进基因公司(Digene)以及后来在中美两地的创业生涯中,一直从事分子医学研究和靶向药物研发创制,并在跨国生物医药企业创建和管理领域积累了丰富的实践经验,是国际基因治疗和纳米颗粒载体的资深专家,并是国际核酸干扰药物开发领域著名专家和连续创业者。
从作为联合创始人创立Intradigm公司开始(2000 - 2006)到创始人创立圣诺制药(2007年以来), 陆博士参与和带领团队在美、中陆续集融资超过9000万美元。陆博士已经陆续发表了60多篇科学论文,并是50余项已授权或者正在申请的国际和中国发明专利的发明人。陆博士曾经获得美国国家健康研究院和马里兰州政府的多项研发资金支持,并在中国主导了多项包括国家“十一五”、“十二五”、“十三五”国家重大新药创制专项等国家、省、市和地方的科研基金项目,并被获得多项荣誉奖项。
陆博士早年毕业于广州中山大学并取得博士学位后赴美(1987)在马里兰大学和乔治城大学从事博士后研究。陆博士是美国华人生物医药科技协会(CBA-USA)共同创始人和第二任会长,现任广州市生物产业联盟(GZ-BIO)秘书长。
Xiayang Qiu
Founder & CEO
Qilu Regor Therapeutics
Dr. Qiu is the CEO of Qilu Regor Therapeutics, an innovative drug discovery company he founded together with a team of accomplished scientists and executives from top global pharma companies. Located in Shanghai, Boston and San Diego, Regor leverages world-class expertise in Computer Accelerated Rational Discovery (CARD) and efficient R&D ecosystems to accelerate the delivery of novel therapeutic agents with high unmet medical needs for patients in China and around the world.
Before returning to China in 2018, Dr. Qiu was Executive Director & Head of Structural & Molecular Sciences at Pfizer. He built and led a team of ~60 scientists with industry-leading expertise in structure-based drug design, computational sciences, and integrated molecular mode of action approaches. Prior to joining Pfizer in 2001, he was a member of GSK Global Target Evaluation Meeting and Novel Targets Committee. In 25 years in industry, he has contributed to 30 clinical candidates across diseases areas (inflammation & immunology, neurosciences, oncology, cardiovascular & metabolic, infectious & rare diseases) and therapeutic modalities (small molecule, ADC, biologics & vaccine). He discovered PCSK9 molecular mode of action that led to the industry-wide shift from seeking protease inhibitors to antibody therapies. He built the first cutting-edge cryo-EM lab in industry & New England, and delivered multiple clinical candidates using fragment-screening. He also served as President of New Drug Research for Qilu, one of the biggest pharmaceutical companies in China.
Dr. Qiu graduated from Peking University, obtained PhD at Michigan State, and completed executive trainings at Harvard Business School. He was an NIH Fellow and HHMI Research Associate at University of Washington in Seattle. He has trained 15 postdocs, served on expert review panels for National Institute of Health and other US funding agencies, and has been a member of Faculty of 1000 since 2004. He has >6000 citations (h-index 39) from over 60 publications, including in top journals such as Nature and Science.
Chris Lai
Chief Executive Officer
METiS Pharmaceuticals
MIT博士,药品制程及新药数字化战略专家,曾任职于诺华-MIT中心,麦肯锡顾问,AquaFresco创始人
Li Wang
Sr. Vice President and Head of Lilly China Drug Development & Medical Affairs Center (LCDDMAC)
Eli Lilly
Education & Academic Career:
• Postdoctoral Research Follow,
Massachusetts General Hospital, Harvard Medical School • M.D. ,Ph.D.
Shanghai Medical School, Fudan University

Industry experience:
• June,2017 to present
Sr. Vice President, LCDDMAC, Eli Lilly China
• Sep, 2010 to June, 2017
Vice President in LCDDMAC, Eli Lilly China,
• Apr 2007 to Sep 2010
Oncology Medical Director of GlaxoSmithKline China/HK
• Sep. 2001 to Mar. 2007
Oncology Chief Clinical Research Physician, Eli Lilly China
Zhengqing Li
Vice President and Head of MSD China R&D
MSD Research Laboratories
Zhengqing Li is the Vice President and Head of MSD China R&D. In this position, he is responsible for the operation and strategic direction of MSD R&D Center in Beijing. As the China R&D head, Zhengqing leads a development team whose primary mission is to bring innovative medicines and vaccines effectively and efficiently to meet unmet medical needs of Chinese patients. In addition, Zhengqing plays the leadership role in building MSD global capabilities in China, and in establishing external collaborations with research institutes, professional societies and industry partners. Under his leadership over the past 8 years, the MSD China R&D Center has been growing dramatically with more than 1000 scientists with expertise across Clinical Research, Regulatory Affairs, Clinical Trial Operations, Pharmacovigilance, Project Management, Biostatistics, Epidemiology, and Data Management, etc.
Prior to joining MSD, Zhengqing took a number of leadership roles with Bristol-Myers Squibb (BMS) including the Head of Clinical Research, China R&D and Executive Director and Head of Oncology & Neuroscience, Global Biometric Sciences. Prior to joining BMS, Zhengqing also worked with Pfizer and Procter & Gamble Pharmaceutics with increasing responsibility in drug development.
Zhengqing has authored and co-authored more than 40 scientific and clinical trial methodology papers and abstracts. He has played leadership role in the development and approval of nearly 20 drugs in China and United States. Which including famous HPV vaccine GARDASIL and GARDASIL 9, chronic HCV drug ZEPATIER and key product of immunotherapy KEYTRUDA, etc.
Zhengqing was born and grew up in China. He received his undergraduate education at University of Science and Technology of China and his PhD degree from University of Wisconsin-Madison with major in Biostatistics. Upon completion of his PhD, Zhengqing took a faculty position in the School of Public Health at State University of New York.
Steve Chin
Chief Medical Officer
Elpiscience Biopharma
Dr. Chin’s career spans over 20 years of experience in medical oncology and clinical development in the pharmaceutical industry. In January 2020 he was appointed as CMO at Elpiscience Biopharma.
Prior to joining Elpiscience, Dr. Chin was a Senior Medical Director of immuno-oncology, Global Clinical Development at AstraZeneca. There, Dr. Chin provided leadership and expertise to enable new investment decisions in oncology therapeutic development, which involved the successful development of clinical strategy, determining the direction of regulatory interaction and coordination/execution of new clinical trials. Prior to his career at AstraZeneca, Dr. Chin was a Global GI Oncology Lead at Eli Lilly. He was involved in the transfer of cetuximab (Erbitux) full rights in North America from BMS to Lilly, led regulatory submission for Erbitux label updates, and fulfilled Erbitux post-marketing commitment.
Dr. Chin started his career as a medical oncologist and served as an assistant professor in the Division of Hematology/Oncology at the Medical University of South Carolina in Charleston. He was a clinical investigator with a special interest in cancer therapeutic development and correlative studies. Over his career, Dr. Chin has served as PI or Co-I in over 20 active clinical trials. He is currently a member of the executive committee for the Chinese American Hematology and Oncology Network, a non-profit organization focused on fostering exchange of medical information between United States and China in the fields of hematology and oncology.
Nanhai He
Head of Biosciences
Adlai Nortye Biopharma
Nanhai He is the Head of Biosciences of Adlai Nortye who has over 15 years of experiences in research / target identification, and multidisciplinary background with past experience in biochemistry, immunology and metabolism. Dr. He received his Ph.D. in Molecular and Cell Biology from University of California, Berkeley, and finished his postdoctoral training at the Salk Institute for Biological Studies. Dr. He has published more than 20 papers his research field.
Xiaoning Guo
Vice President, Head of R&D and Chief Medical Officer
SciClone Pharmaceuticals
Dr. Xiaoning Guo is currently the vice President, Head of R&D and Chief Medical Officer of SciClone Pharmaceuticals co., LTD. He is fully responsible for R&D of pipeline drug candidates and life cycle management of post-market products. Dr. Guo graduated from Shanghai Institute of Materia Medica, Chinese Academy of Sciences with a PhD in pharmacology. Later, he went to the United States and worked as a research affiliate at Roswell Park Cancer Institute, a National Comprehensive Tumor Hospital and Cancer Center. In 2007, Dr. Guo came back to China and joined MNCs including Astrazeneca and Johnson & Johnson to in charge of translational medicine project, clinical Phase I to III project development and portfolio management. After a couple of years, Dr. Guo joined Covance as a senior Director, Clinical Drug Development Leader in Asia Pacific region, responsible for the development and implement of the global development strategy of the project. Dr. Guo has accumulated extensive experience in different stages of drug development from preclinical including biomarker research to translational medicine to clinical development. Before joining SciClone, Dr. Guo served as deputy General Manager and Chief Medical Officer of General Regeneratives, co., Ltd., responsible for clinical development and regulatory affairs department.
Joe Zhou
President and Chief Scientist
Genor BioPharma
Visiting Professor
Peking University
Previously, Dr. Zhou was Scientific Director at Amgen, Thousand Oaks, USA. His over 20-years experience of process development, multiple project management capacity in cGMP and non-GMP reproducible purification/production of protein/antibody therapeutics from FIH to CPD with depth knowledge of CHO clone selection, cell culture optimization, real time analytical assays, formulation and product specification for drug substances and drug products made Dr. Zhou many times as Project Process Team Leader/Project Team Leader/Cross Functional Core Investigation Teams Leaders at Amgen in the past.
Dr. Zhou has proven bio-industrial leadership in scientific innovation and technology evaluation, and is well known for implementation of membrane chromatography in mAb large-scale processing. Dr. Zhou has excellent reputation and an extended external network in the Process Development and or Process science peer community due to his extensive speaking and publication record including research articles, patents and book chapters in the Process Development and Process science field. Dr. Zhou has proven records for design space for process robustness and viral clearance in mAb production. Dr. Zhou was awarded as 2007 Amgen’s “Excellence n Science and Engineering” for his major achievement and leadership on photo-oxidation on monoclonal antibody yellowing, and selected by Amgen as a visiting professor teaching the GMP Master’s Degree Program at PKU, People’s Republic of CHINA since 2007.
Maggie Gu
Vice President, R&D Shanghai Innovation Hub
Ipsen
Maggie Gu (Juanhong) is Vice President – R&D Shanghai Innovation Hub at Ipsen, a leading biopharmaceutical group dedicated to improving lives through innovative medicines in oncology, neuroscience and rare diseases.
Maggie has over 20 years of experience in clinical development, Medical affairs and Clinical Research operations in pharmaceutical indursry. Prior to Ipsen, she was Vice Present – Clinical research and operatnions in Junshi Bioscience, where she led and contributed to regulatory approval of the first China-developed PD-1 anti-body.
She started her career in the pharmaceutical industry as a Clinical Research Associate in Daiichi in 1997, and worked through the roles as Clinical Research Project Manager in MSD, Medical affairs manager in Fujisawa, Head of Clinical Operations and Therapeutic Area Medical Science Director at GlaxoSmithKline, as well as the Senior Director-Clinical Development in Clinical Operations at AstraZeneca.
She has successfully led development and registration activities of a series of innovative products in Oncology, Dermatology, Respiratory and other areas in China, including Tuoyi, Tagrisso, Botox, Avodart, Protopic etc. Prior to joining the pharmaceutical industry, Maggie worked in the Pediatric Research Institute,
Children’s Hospital affiliated to Shanghai Medical University. She holds a Master‘s degree in Pediatric Medicine from The Shanghai Medical University.
Xiang Yang Zhu
Chief Executive Officer
Huaota Biopharm and Huabo Biopharm
Dr. Zhuis an expertin antibody drug discovery and process developmentwith more than 18 yearsof industrial experience. Hehas extensive experience in antibody drug discovery, process development, and manufacture facility construction. Dr. Zhu is the CEO for both Huaota Biopharm and Huabo Biopharm (members of Huahai Pharm), leads its global biotherapeutic research.Prior to join Huahai, he worked at Boehringer Ingelheim for more than 8 years in different function areas at multiple locations (Ridgefield, USA; Biberach, Germany; and Shanghai, China). He led andengaged inover 20 global BI biological research projects including current clinic Phase I-III projects and market products; Dr. Zhu obtained his PhDin microbiology and immunology fromtheUniversity of Illinois at Chicagoand has authored more than 20 publications in peer-reviewed journals.
Siying Peng
President and CSO
IDMO
彭思颖, 哈佛医学院附属免疫疾病研究所博士后。北京市省部级人才、“高聚工程”、“亦麒麟”人才,“科技新星计划”入选者,现任北京艾德摩生物技术有限公司总裁兼任首席科学家,专业擅长肿瘤转化医学及实验动物学。带领团队成功研发出免疫重建人源化动物模型构建技术, 人源化异种移植(PDX)小鼠模型构建技术以及创新型肿瘤药物临床前评价平台。
Wen Luo
Chief Executive Officer and Chief Scientific Officer
Denovo BioPharma
Dr. Wen Luo has over 20 years of experience in biomedical research and industry including more than 15 years of experience in applying genomic technology in drug discovery and development. Prior to founding Denovo Biopharma, Dr. Luo managed the genomic group and provided bioinformatic support to a broad range of research projects across a number of therapeutic areas including oncology, hematology, inflammation and metabolic diseases at Ligand Pharmaceuticals. He was also responsible for developing clinical biomarkers for drugs in various stages of clinical trials. Before joining Ligand, he was a senior scientist for bioinformatics at Incyte Genomics, where he managed one of the largest proteomic databases, LifePro. He was also involved in discovering novel human genes and splice variants, and was the co-inventor of patents covering hundreds of novel genes derived from these findings. Prior to Incyte Genomics, he was a research scientist at Sugen, which had been acquired by Pharmacia, where he worked on drug target identification and validation for a number of novel kinases discovered at Sugen. Dr. Luo was a Howard Hughes Medical Institute post-doc fellow at the University of California, San Francisco, and received his Ph.D. in Molecular Biology and Biochemistry from Indiana University School of Medicine. Dr. Luo received pre-med training at Peking University and medical training at Peking Union Medical College.
Reako Ren
General Manager, Head of SMO Services
WuXi AppTec
任科,现任上海药明康德新药开发有限公司副总裁,SMO事业部津石医药总经理,在生物医药研发领域拥有19年相关经验。他在阿斯利康、PPD、西斯比亚等跨国药企、CRO、SMO工作多年,从事新药临床研究相关的战略发展,运营管理,业务拓展等专业工作,在肿瘤、呼吸、心血管、内分泌、感染、消化、神经内科等参与过上百项创新药的I-III期临床研究工作,在相关专业杂志发表十余篇文章并在药物临床试验机构联盟和DIA等多个学术机构担任学术职务。 任科领导着目前中国最大的临床研究执行团队,在全国142个城市有3000多专业的研究人员,与上千家研究中心进行了超过1000项临床研究项目的实施,在过去4年已经帮助50多个产品顺利通过药监局核查上市,通过率100%,其中包括中国首个PD-1产品的上市,中国首款宫颈癌疫苗的上市,中国研发的首个欧盟批准上市的生物类似物上市,中国首个以真实世界数据支持的医疗器械产品上市等突破性项目的成功实施。他还带领团队建立了行业里非常领先的CTMS数据中台,整合了全公司所有的项目、人员、医院信息、财务、商务、HR等板块业务流和数据流的一体化平台,积累了大量临床研究操作执行的第一手数据,为行业赋能,并因此获得上海市发改委现代服务业资助项目一等奖。
Jin Li
Founder, Chairman and CEO
HitGen
Dr. Li is the founder, Chairman and CEO of HitGen Inc., and also a Fellow of the Royal Society of Chemistry and a Guest Professor of Sichuan University, etc. Dr. Li has over 30 years biopharmaceutical experience (at Protherics, AstraZeneca, HitGen), with senior scientific and leadership roles in early stage research; as well as experience in initiating and leading major collaboration, research and outsourcing programmes. Dr. Li held Global Director positions of Compound Sciences and Computational Sciences at AstraZeneca, which included molecular design, synthesis and screening. Dr. Li has published more than 30 papers and 20 authorized patents.
Since its foundation in 2012, HitGen has developed into one of the most influential companies in the field of novel drug discovery research centered on DNA Encoded Chemical Libraries (DELs). HitGen has established extensive international R&D collaboration and its own new drug pipelines. HitGen (688222.SH) became a listed company on the Science and Technology Innovation Board in Shanghai Stock Exchange on April 16, 2020.
TJ Deng
GM and CEO
BioDuro China
邓天敬博士,保诺科技中国区首席执行官,清华大学医学院客座教授。
美国马凯特大学(Marquette University)生物分析化学博士,曾参与了多个药物在美国FDA的申报,作为美国 FDA主导的制药行业产品质量研究院(PQRI)的 药品包装萃取物和渗透物( extractable/leachable)专家组成员 ,为 FDA起草了全球第一份药品包装萃取物和渗透物指南性文件。作为保诺科技中国区的领导人,邓博士成功带领上海研发团队在2015年实现上海分公司业绩500%的增长。
Hequn Yin
Chief Scientific Officer
Qilu Pharma
Hequn Yin is currently CSO of Fosun Pharma. Prior to joining Fosun, Hequn was a VP of Pfizer Oncology R&D in California, USA. Before Pfizer, he spent nearly 20 years with Novartis in New Jersey, USA where he held positions of increasing responsibility from a Sr scientist to an Executive Director. Hequn also worked at Hoffmann-La Roche in New Jersey during 1997-98.
Hequn received a B.S. in chemistry from Peking (Beijing) University in 1985 and a M.S. from the Chinese Academy of Sciences in 1988. He earned a PhD degree in pharmacology from the University of Rochester, USA in 1995. Subsequently he conducted post-doctoral research in molecular biology & biochemistry at UC San Francisco, USA between 1995 and 1997. He also attend the eMBA program at Fairleigh Dickinson University in New Jersey.
Jonathan Wang
SVP, Head of Business Development
Zai Lab
Jonathan Wang is our head of business development since 2014. Prior to joining Zai Lab, Mr. Wang was an investment professional at OrbiMed, where he was responsible for China healthcare investment and portfolio management. From 2005 to 2011, Mr. Wang worked as a consultant at the Boston Consulting Group in China, where he specialized in pharmaceutical and healthcare engagements, assisting multinational and local companies with their China strategy. Previously, Mr. Wang also gained financial transactional experience at Goldman Sachs Investment Banking. Mr. Wang received a master of business administration in healthcare management from Wharton Business School.
Feng Bian
Senior Director & Asia Emerging Science Lead (Shanghai), Asia Discovery Labs, Emerging Science & Innovation (ES&I)
Pfizer Worldwide Research & Development
Dr. Feng Bian is a Senior Director and Asia Emerging Science Lead in Pfizer Asia Discovery Labs (ADL) of Pfizer’s Worldwide Research and Development. She is responsible for cultivating strong and in-depth scientific relationships with Asia Academic and Life Science Communities with a primary focus on southern China regions to access emerging sciences, promising compounds, and breakthrough technologies.
Prior to ADL, Dr. Bian was a senior investigator in China Novartis Institutes for Biomedical Research and group head of liver pharmacology since 2014 in Shanghai. At Novartis, she was a project leader and managed liver disease pharmacology platform to deliver data packages for drug discovery projects. Before Novartis, she was a key scientist participated in setting up JnJ China research labs in 2012, and Associate Director of Biology to manage CROs and academic collaborations as well as internal R&D programs. Dr. Bian began her R&D career in Parke-Davis/Warner-Lambert in US as an in vivo pharmacologist in the Neuroscience Division, and later became a principle scientist in Pfizer’s Neurodegeneration and Psychotherapeutics Unit, contributing to programs like Lyrica®, discovery programs for Alzheimer’s disease, bipolar depression and dermal fibrosis. Dr. Bian has 20 years of expertise in small molecule and biologics drug discovery and her work has enabled NMEs to reach first in human. Dr. Bian received her Doctorate degree in Biochemistry from The Ohio State University and her Bachelor of Science degree from Nankai University at Tianjin, China.
Qun (Max) Dang
Corporate Vice President, President, CEO
CSPC, CSPC Shanghai Research Institute, InnovStone Therapeutics
Max received his BS from Jilin University with honors and earned a CGP national scholarship sponsored by the Chinese government; he obtained his Ph.D. in organic chemistry from Purdue University in 1992, joined Gensia (later became Metabasis) as a medicinal chemist and worked until 2009 with his last position as director of medicinal chemistry. Max then joined Merck as a Senior Investigator in the External Basic Research department, and then from 2011 to 2013, he was Director of External Medicinal Chemistry, Asia Lead, based in Shanghai facilitating Merck-CRO operations; 2013-2016, he was a Principle Scientist in the exploratory chemistry department at the Kenilworth site. In 2016 he joined Eli Lilly as Asia Head, BD and External Innovation for diabetes and CV research and worked until March 2018 before joining Qilu Pharmaceutical as VP, Global Head of BD and External Innovation with responsibilities for all BD and external collaborations globally including in-license, out-license and setting strategies for drug discovery and external collaborations. In June 2019, Max joined CSPC as corporate VP, President of CSPC Shanghai Research Institute, CEO of InnovStone Therapeutics, responsible for small molecule new drug discovery efforts. Max has extensive experiences in business development globally and more than 25-years of experiences as a manager of drug discovery programs spanning from early (Target Selection and Validation, Lead Identification) to late (Lead Optimization and candidate selection) stages; led programs that advanced multiple compounds into human clinic trials (two completed Phase 2b POC studies); experiences in therapeutic areas including diabetes, dyslipidemia, hepatitis B and C, liver cancer, liver fibrosis, anemia, viral and bacterial infections; extensive knowledge of Structure-based Drug Design, Medicinal Chemistry, Drug Delivery, Prodrugs, Liver targeting Strategies, Combinatorial, Heterocyclic and Nucleoside Chemistry; more than five years of managing drug discovery programs executed at various CROs. His research activities have led to 91 publications and 60 patents.
Jingye Zhou
Chief Executive Officer and Co-Founder
Eccogene
Dr. Zhou is Chief Executive Officer and co-founder of Eccogene. Prior to founding Eccogene, Dr. Zhou was the head of chemistry at Lilly China R&D Center, where he led project teams to achieve candidate selection milestones for diabetes and diabetic complications. Before joining Lilly in 2012, Dr. Zhou was investigator at GlaxoSmithKline working on drug discovery campaigns utilizing disruptive DEL technology. Dr. Zhou began his career at Tetraphase pharmaceutical, where he co-invented Eravacycline, an FDA approved drug for cIAI. He holds a Ph.D. in chemistry from Brandeis University and received a B.S. in life science from Fudan University.
Dadong Li
BD & Licensing Manager
Roche Pharma Partnering
Dr. Dadong Li is currently a BD & Licensing Manager with Roche Pharma Partnering, based in Shanghai office. He is in charge of BD efforts in China across various therapeutic areas, from preclinical to late stage, and represent both Roche and Genentech. Prior to joining Roche, Dadong was a commercial officer with UK Department for International Trade at British Embassy in Beijing, where his responsibility is to facilitate UK China investment and trade in healthcare sector. Dadong also worked as a management consultant with PwC Management Consulting on strategy for healthcare companies and he has experience with Chinese Academy of Sciences as a junior scientist.
Dadong holds a Ph.D. in Chemistry from New York University, and a Bachelor degree in Materials Chemistry from Peking University.
Zhao-Kui (ZK) Wan
Fellow of the Royal Society of Chemistry, Founder & Chief Executive Officer
Lynk Pharmaceuticals
Dr. Wan is the founder and CEO of Lynk Pharmaceuticals, a VC supported biotech company focusing on oncology, auto-immune and inflammatory diseases. Dr. Wan earned his Ph.D. degree from Boston University, then conducted a postdoctoral research at Harvard University. Before starting Lynk Pharmaceuticals, Dr. Wan served as the Head of Chemistry at JNJ’s Asian Pacific Discovery Center with various cross-function responsibilities. He was one of the key leaders and played an instrumental role of building the Center from its earliest inception. Prior to JNJ, Dr. Wan had worked for Wyeth/later Pfizer for a dozen years and served as a group & project leader as well as a postdoc research advisor.
Dr. Wan has research experiences in multiple therapeutic areas and made significant contributions to the development a number preclinical candidates, clinical compounds and marketed products. Dr. Wan has more than 50 scientific publications in peer-reviewed journals and meeting abstracts; he also has close to 140 world and national patents. Dr. Wan won a number of awards and recognitions; he is an elected Fellow of the Royal Society of the Chemistry (2015), a winner of Young Industrial Investigators Award (ACS, 2008) and a steering committee member of Chemistry in Cancer Research of AACR (2017). Dr. Wan is a co-founder & a member of Board of Directors of Chinese BioMedical Association (CABA) and served as the President (2009- 2010). He is also a member of many prestigious professional organizations such as AACR, BayHelix and ACS.
Previous Speaker Bio
Min Li
Vice President, Analytical Operation
Huahai Pharmaceutical
Dr. Min Li received his PhD in Organic Chemistry from Johns Hopkins University in 1991. Following a postdoctoral research in medicinal chemistry, he had worked for several multinational pharmaceutical companies with increasing responsibilities, including Roche, Merck & Co., Inc. Schering-Plough, and Merck again. Over the years, he has led technical teams of senior-level scientists for various analytical and pharmaceutical manufacturing process investigations and troubleshooting, impurity peak identification, study of drug degradation chemistry, analytical development, and support for new drug filing. Since September 2014, he became Vice President for Analytical Operation at Huahai Pharmaceutical, a leading Chinese pharmaceutical company with operations in both China and US. He also established the Center of Excellence for Modern Analytical Technologies (CEMAT), a technical core group created for solving the most challenging technical problems from pharmaceutical R&D to scale-up and commercial production at the company.
Dr. Li is a leading expert in drug degradation chemistry and he published a single-authored book, “Organic Chemistry of Drug Degradation” (by Royal Society of Chemistry) in 2012; the Chinese translation of this book was published in September 2019. He is the first/communicating author of more than 50 publications in organic, medicinal, bioconjugate, and analytical chemistry (including mass spectrometry). He is currently a member of the expert committee (Chemical Medicines 5) at United States Pharmacopoeia (USP) and a board member of Sino-American Pharmaceutical Professional Association (SAPA).
Zhenping Wu
Senior Vice President, Pharmaceutical Sciences
Hutchison MediPharma
药学研发专家,具近30年药学开发经验。领导过多个项目的研发团队,将多个新药候选药物推进至临床各个阶段和市场,包括舒尼替尼(Sutent)——由辉瑞研发的新型具重磅炸弹潜力的抗癌药物。吴振平博士于2008年起至今任职和记黄埔医药,负责组建药学和生产部门。公司已经成功将十数个研发药品推向临床研究,包括在中国和美国进行的研究。多个项目已经进入或完成三期临床研究,其中抗癌新药呋喹替尼已经上市。
吴博士曾在位于加州的药物研发公司Phenomix任药学部高级总监。在此之前,他曾担任辉瑞圣地亚哥全球研发中心(前称为Agouron医药公司)药物开发部总监,更早之前在罗氏加州研发中心(Roche Palo Alto)任资深科学家。吴博士于香港大学获得博士学位并在加州大学尔湾分校取得了MBA学位。他曾任中美生物技术和制药协会理事长和会长。2003年,他因舒尼替尼(Sutent)项目获得辉瑞杰出员工奖。他带领的索凡替尼课题组荣获2010年度和记黄埔医药优秀团队奖。
Ming Guo
President & COO, Co-Founder
Ascentage Pharma
Dr. Guo has been working in the healthcare industry since 1991, including ABC Laboratories, Pfizer, Ascenta Therapeutics, and Ascentage Pharma. At Pfizer (1995-2005) with various technical and management roles, Dr. Guo participated in many NCE drug R&D projects, several of which have successfully reached commercial stages. At Ascenta (2005-2009), Dr. Guo was the founding Vice President of Pharmaceutical Sciences & Manufacturing, and also General Manager of Ascenta (Shanghai) R&D Center which engaged in NCE drug R&D in China from 2005. Dr. Guo played an important role in Ascenta’s >$600M global out-licensing deals (i.e., with Sanofi-Aventis in 2010 and with Debio in 2011). Dr. Guo co-founded Ascentage Pharma in 2009, a globally positioned China innovative NCE drug R&D company, and currently serves as President & COO. The company has quickly built up a pipeline of 8 clinical-stage NCE projects along with several IND-enabling and discovery stage projects, covering oncology and anti-aging / anti-viral therapeutic areas through its apoptosis/PPI platform. During 2002-2005, Dr. Guo served as an Overseas Advisor for Beijing Zhongguangcun Biotech Park in China. He has been an adjunct professor, a faculty and graduate student adviser for the IPEM program at Peking University during 2007-2018. Dr. Guo served as an Independent Board Director at Porton Corporation (Chongqing, China) during 2012-2016, overseeing its successful IPO at Shengzhen Exchange, China, in 2014. As a co-founder and the founding Chairman, Dr. Guo has served on Board of Directors of SABPA (www.sabpa.org). Dr. Guo received his Ph.D. degree in Organic Chemistry at the University of California at San Diego; M.Sc. in Medicinal Chemistry at Institute of Materia Medica, Chinese Academy of Sciences; and B.S. in Chemistry at Peking Normal University.
Steven Hu
Senior Vice President, CMC and Supply Chain
Everest Medicines
Dr. Steven Hu currently is the Senior Vice President of Everest Medicines, being responsible for CMC and supply chain. Before he was the Senior Director of CMC in Roche Pharm Research and Development (pRED) Shanghai, heading process research and synthesis, analytical, preformulation and formulation development to support Roche China portfolio. Before joining Roche, Steven was the Director of New Product Development (NPD) of GSK China R&D, overseeing the whole drug product development life cycle from formulation development and optimization, process development and scale-up to technology transfer to commercial manufacturing. Steven had worked in Merck (West Point, PA) and J&J (Spring House, PA) respectively in the United States before coming back China in 2010.
Steven obtained his Ph.D. in Chemical Engineering from Brown University, USA, and then spent about two years at MIT as a Post-doctoral Research Fellow.
Yi Hsiao
Senior Vice President of the Center of Project Process R&D
AsymChem
肖毅博士于2018年9月加入凯莱英医药集团担任项目研发中心高级副总裁,负责工艺开发,导入提高研发水平和效率的新技术,以及工艺研发与上下游部门间的协调与整合。肖博士1991年获日本名古屋大学博士学位(师从2001年诺贝尔奖得主野依良治教授)、后在美国科罗拉多州立大学L. Hegedus教授研究室进行博士后研究。肖毅博士曾任职于美国默沙东和施贵宝的工艺部门,有超过20年的制药工艺的研发经验,并为施贵宝公司创建了催化剂研究实验室,导入高通量筛选技术和以数据库为基础的工作流程。期间参与了数十个研发项目。已经发表过50篇论文,赢得了包括绿色化学总统奖在内的多个国际大奖,在世界各地发表过40余次的学术讲演,目前是2018年制药化学反应与工艺会议的组委会成员之一,2019年美国有机反应与工艺的Gordon会议的工业界主席。
Jim Li
Chief Executive Officer
Sundia
Dr. Jim Li is chief executive officer of Sundia. In this role, Dr. Li is responsible for the oversight of all business divisions across the organization as well as formulating and driving key strategies for diversifying and growing the company. Dr. Li also leads the company’s executive committee, helping to drive Sundia’s overall global strategy.
Dr. Li has led a distinguished career in the pharmaceutical industry, having spent over 18 years at various companies including Henkel, Wyeth, Pfizer and Wuxi Apptec in the area of process research and medicinal chemistry. During his career, he was involved in numerous drug discovery programs such as COPD, asthma, Rheumatoid/osteoarthritis, and diabetes. Dr. Li has co-authored more than 60 research articles and patents.
Dr. Li received his Ph.D in Organic Chemistry from University of Central Lancashire UK followed by a postdoctoral fellow at the University of Chicago with Dr. Philip Eaton.
Deepak Hegde
Chief Technology Officer
EOC Pharma
Dr. Deepak Hegde completed his Doctorate in Biopharmaceutics and Pharmacokinetics from University of Mumbai in 1996. He also completed his Masters in Financial Management (M.F.M) from University of Mumbai in 2000.
He is currently working with EOC Pharma as Chief Technology Officer, responsible for development and manufacturing of new speciality anti cancer products for China. Prior to joining EOC, he was with GSK Shanghai, R & D China as Director, Global External Development & Supply, AsiaPacific, responsible for developing drug products for GSK global portfolio and for introduction of new products to China. Prior to this he worked with Wuxi AppTec as Vice President for Formulation Development. At WuXi Apptec, he was instrumental in setting up the Formulation Development Business as well as the formulation team, GMP facilities and systems which have since been approved by the EMA, USFDA and CFDA. While working with several multinational companies from US and Europe, he helped develop more than 150 NCE’s. He established several enabling technologies like Microdozing, Nanonization, Spray Drying, and Holt Melt Extrusion (HME) etc. at WuXi AppTec which helped customers expedite the First in Man (FIM) studies in US, Europe, Australia, Korea & China. Prior to joining WuXi AppTec in Shanghai, he has worked at several positions across Rhone Poulenc, Sandoz (A Novartis Group Company) and USV Ltd, a premier Indian Generic Company.
He has extensive experience in generic formulation development of solid and liquid oral and injectible formulations from a very early phase of development all the way to technical transfers to commercial manufacturing sites. At Sandoz, he worked on formulation development for the regulated markets like US and Europe and participated in technical transfers to commercial sites of Sandoz at Rolab in South Africa, and Novartis Bangladesh and Novartis Pakistan. Several generic products that he developed have since been registered and commercially launched in Europe, USA, South Africa and Asia. He is a life member of the Indian Pharmaceutical Association. He has two US patents, five PCT and US patent applications and several National and International publications to his credit.
Yuanhui Ma
Executive Director and CMC Head
Shanghai HaiHe Pharmaceutical Co.,Ltd.
Dr. Ma obtained his Ph.D. from Shanghai Jiao Tong University, and went on with organocatalyst research in NTU as a postdoctor. He has 10 more years of experience of drug R&D and management, focus on CMC. Dr. Ma joined HaiHe in mid of 2016, and set up CMC department. He oversees CMC development and DS/DP manufacturing for all HaiHe’s pipeline products
Shijie Zhang
Chief Technology Officer
PharmaBlock
Dr. Shijie Zhang, currently serving as Chief Technology Officer at PharmaBlock, is leading initiative to extend the team’s competence in process development and manufacturing to support clients’ late phase and commercial programs. Dr. Shijie Zhang has 20 years of combined experience in medicinal chemistry, process chemistry, and API manufacturing. Before joining PharmaBlock, he led the CMC API team at Agios for the two FDA-approved therapies (Idhifa®, Tibsovo®), by managing and overseeing API development programs and manufacturing activities spanning from preclinical stage to commercial stage, and preparing API sections of regulatory filing documents, including IND, IMPD, NDA, and briefing documents.
Bo Shan
Vice President, Discovery and Early development
Antengene
单波博士具有超过17年在欧美,中国的新药和仿制药研发和生产经验。目前是德琪医药负责药物早期研发和生产的副总裁。单波博士曾经带领团队完成共计1个国家一类新药的申报上市,多个处于I-III期临床试验的一类新药,以及一系列临床前的项目开发。单波博士带领团队完成了一个国家一类新药生产基地从设计,土建,装修,设备采购到工艺验证和试生产的全过程,包括两条API生产线,一条固体制剂生产线,并且于2018年通过了国家注册现场和GMP动态核查。
单波博士曾先后担任歌礼药业副总裁,凯惠药业(上海)有限公司常务副总经理,上海睿智化学研究有限公司执行总监,GE Healthcare英国研发中心科学家等职务。单博士具有英国Aston大学药物化学博士学位。
谢沐风
副主任药师
上海市食品药品检验所
1990年~1995年 沈阳药科大学 日语药学专业本科毕业
1995年~1998年 沈阳药科大学 药物分析专业硕士研究生毕业
1998年~至今 上海市食品药品检验所工作 专业职称:副主任药师
主要从事化学药品的仿制药复核、药典起草、进口药品质量标准复核、现场考核和质量标准制订等工作。
2003年8月 ~ 2004年2月
赴日本国立医药品食品卫生研究所(即国家药品检验所)药品部进修。
详细了解了发达国家对于药品的审评要点与技术要求;师从《日本药品品质再评价工程(即仿制药质量一致性评价)》“总设计师”系统学习了实施细节与技术应用,掌握了“如何采用多条特征溶出曲线评价口服固体制剂品质”方法与手段,深刻了解了溶出度试验对于仿制药的重大意义和举足轻重的作用,以及发达国家如何提高和控制药品内在品质的具体措施与手段。
截止目前,发表了80多篇药品品质评价方法的思路类文章,尤多篇溶出度和有关物质研究文章引起业内瞩目。
2007年1月 曾担任国家发改委价格司药品价格处顾问。
2008年起~至今 担任国家药品监督局高级培训学院、全国医药技术市场协会等“化学药品质量研究”授课教师。
2009年1月、在国内知名的药学网站——丁香园创立“溶出度研究”专栏,登载了撰写的10多万字相关内容。
2009年~2012年 任国家食品药品监督管理局市场监督办公室专家顾问 负责指导“全国评价性抽验工作”,并首次全面引入了“如何利用体外多条溶出曲线评价口服固体制剂内在品质”的作法,发现了部分国产上市品体外多条溶出曲线与原研品的显著性差异,从而为临床疗效和毒副作用上的差距提供了佐证,为2012年初国家推出“仿制药质量与疗效一致性评价工作”奠定了基础。
2010年 曾担任国家药品审评中心顾问,主持编译了《日本橙皮书——多条溶出曲线数据库》和《日本仿制药生物等效性试验系列指导原则》等。
2012年6月~2013年10月 担任《国家仿制药一致性评价项目》办公室专家,参与起草了《如何测定原研制剂多条特征溶出曲线指导原则》、《如何进行仿制品与原研品多条溶出曲线比较指导原则》和具体品种比较法。
2013年12月 在国内知名药学网站——丁香园创立“杂质研究与品质评价”专栏,登载了撰写的10多万字相关内容。截止目前,溶出度专栏和杂质专栏的内容已成为国内研发人员的《必读手册》。
担任《中国医药工业杂志》、《药品评价(医院药学版)杂志》编委
Shih-Ying Chang
Vice President and CMC Head
Dizal Pharmaceutical
Shih-Ying joined Dizal at January 2019 as the CMC head for API and drug products development, Clinical manufacturing, and supply chain management. Before coming back to Shanghai, he has worked in Pharmaceutical Development in Bristol-Myers Squibb at New Brunswick New Jersey for 13 years. During the tenure in BMS, he has worked on more than 40 different new chemical entities including Brivanib and Cabozentinib in the oncology area, contributed more than 5 NDA dossiers preparation, especially as the author of the Module 3 QbD sections for Onglyza, which was approved as the first QbD-based NDA filings. Other approved NDAs that he has participated including Sprycel, Kombiglyza, Reyataz, and Daclatasvir. After coming back to Shanghai to join Hutchison MediPharma as the Executive Director of Formulation at 2015, he has contributed to Fruquintinib NDA approval in CFDA. He has also served as the CMC project lead to collaborate with AstraZeneca for the joint global development of Savolitib. In Hutchison he successfully finished two bio-equivalency studies to facilitate formulation changes during pivotal trials.
Jin She
Senior Vice President, CMC
Hua Medicine
Dr. Jin She is Senior Vice President of Chemistry Manufacturing & Control department at Hua Medicine (Shanghai) Ltd. Dr. She has over 16 years’ of experience in the biotechnology and pharmaceutical industry. Prior to Hua Medicine, he worked at MSD R&D Center (China) as Director of Process Chemistry, and Roche R&D Center (China) as Head of Process Research & Synthesis. Before returning back to China from the US, he worked at Inspire Pharmaceuticals Inc. as Sr. Research Scientist and team leader of Process Research. Dr. She has also been an Industrial Advisor for Engineering Master Program at East China Science & Technology University for the last 8 years. Dr. She Received his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill. He obtained his BS and MS degrees in chemistry from Beijing University.s
Tao Feng
Vice President, Head of CMC
Laekna Therapeutics
Dr. Feng is currently Vice President and head of CMC of Laekna Therapeutics. He oversees CMC development and manufacturing for all Laekna’s pipeline products. Dr. Feng has more than sixteen years’ experience in new drug research and development including preclinical development, early phase and late phase product development, clinical manufacturing and process validation towards commercialization. He has led the technical transfer, clinical manufacturing, and process validation of various products, including successful approval and commercial launch of Niraparib in China. Prior to Laekna, Dr. Feng has held various management roles in Zai Lab, WuXi Apptec, and Schering Plough in US. Dr. Feng received his PhD from Purdue University.
Zhixuan Wang
Director, Integrated CMC New Product Program
Sanofi
Dr. Zhixuan Wang is as project CMC operation management role in Integrated CMC New Product Program department at Sanofi China. She Holds Master degree from Peking University and Ph.D from Shenyang Pharmaceutical University. She started her career in drug product development in North China Pharmaceutical Group Corporation. In 2006 she joined in Chinese Academy of Sciences and working on transdermal drug delivery system research work. In 2007, she joined Novartis China as Senior Scientist in Chemical and Pharmaceutical Profiling, Novartis Institutes for Biomedical Research Co., Ltd, and followed GSK R&D China in 2011. Zhixuan has worked on a wide variety of Discovery & Development projects, her role includes compound developability assessment, physical form selection, formulation development, drug product manufacture and clinical supply, CTA/NDA submission and new product launch. She is also involved in Innovative drug delivery system research and development work. Dr. Wang has published ~ 30 papers and patents. Zhixuan has contributed chapters to “Liposome Technology” and “Novel technologies of microencapsulation and the application in DDS”.
胡楠
LC-MS资深应用工程师
安捷伦
胡楠 博士,毕业于浙江大学化学系。长期从事有机分析研究,对反应机理、食品及药品检测、代谢物研究等均有较深入的理解,在国外知名质谱和化学相关期刊发表论文10余篇。现为安捷伦LC-MS应用科学家,负责液质类仪器的应用技术支持。s
王立坤
总经理
海维医药科技
王立坤博士在2018年创立海维医药科技,专注于药物稳定性预测、成药性研究。王博士曾先后任职于Johnson & Johnson Pharmaceutical Research & Development 比利时研发中心,恒瑞医药南京研发中心,曾经成功领导过了多个重磅小分子创新药早期开发、改良型制剂的研发工作。王博士在主持过的研究项目中申请超过20件专利、并在多个国际一流药学期刊学术会议上发表文献。
Asia Pharma R&D Leaders Summit 2021  |  Telephone: +86 21 6157 7321  |  E-mail: kevin.tan@deliver-consulting.com
© 2021 Asia Pharma R&D Leaders Summit 2021- All rights reserved
s